



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



Name	Hidekazu Suzuki, MD, PhD, FACG, AGAF, RFF, FJGES
Affiliation	Tokai University School of Medicine
Country	JAPAN
Major Field	Upper GI diseases and FGIDs

Educational Background	
<b>1983-1989</b>	Keio University School of Medicine, Tokyo, Japan (M.D. June, 1989)
<b>1989-1993</b>	Keio University, Postgraduate Course of Medicine, Tokyo, Japan
<b>1993-1995</b>	Postdoctoral Research Fellow, Institute for Biomedical Engineering, University of California at San Diego, La Jolla, California, U.S.A.

Professional Experience	
<b>1995-2003</b>	Instructor, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
<b>2003-2005</b>	Visiting fellow, Yamagata Technopolis foundation BioRadical Institute
<b>2003-2016</b>	Visiting Assistant Professor, Department of Internal Medicine, Tokyo Dental College
<b>2003-2011</b>	Assistant Professor, Department of Internal Medicine, Keio University School of Medicine
<b>2005-2005</b>	Head, Department of Gastroenterology, Kitasato Institute Hospital
<b>2007-2015</b>	Head of Outpatient Clinic, Division of Gastroenterology and Hepatology, Keio University Hospital
<b>2011-2015</b>	Associate Professor, Department of Internal Medicine, Keio University School of Medicine
<b>2012</b>	Visiting Professor, Department of Gastroenterology and Hepatology, University of Washington Medical Center
<b>2012-present member</b>	<b>Asian Neurogastroenterology and Motility Association (ANMA) Governing Council</b>
<b>2013-2015</b>	Vice director, Division of Gastroenterology and Hepatology, Keio University Hospital
<b>2013-2015</b>	Vice education chief, Keio University School of Medicine
<b>2013-present</b>	Review board member of Grants-in-Aid for Scientific Research of JSPS
<b>2015-2019</b>	<b>Professor, Medical Education Center, Keio University School of Medicine</b>
<b>2015-2019</b>	<b>Professor, Keio University Graduate School of Medicine</b>
<b>2016-present</b>	<b>President of the Japanese Society for Microcirculation</b>
<b>2016-present</b>	Guest Professor, Department of Internal Medicine, Tokyo Dental College
<b>2016-present</b>	<b>Standing committee member of Japanese Medical Specialty Board</b>
<b>2017-2019</b>	<b>Chief, Fellowship Training Center, Keio University School of Medicine</b>
<b>2017-present</b>	<b>International Committee member of American Gastroenterological Association (AGA)</b>
<b>2017-present</b>	<b>Vice President of the Japanese Society for Helicobacter Research (JSHR)</b>
<b>2018-present</b>	<b>Steering Committee member of Japanese Medical Specialty Board</b>
<b>2019-present</b>	<b>Professor, Department of Gastroenterology and Hepatology, Tokai University School of Medicine</b>
<b>2019-present</b>	<b>Director, Division of Postgraduate Clinical Training, Tokai University Hospital</b>
<b>2019-present</b>	<b>Guest Professor, School of Basic Medical Sciences, Peking University</b>
<b>2021-present</b>	<b>Guest Professor of Internal Medicine, Keio University School of Medicine</b>

Other Experience and Professional Memberships	
<b>Associate Editor :</b>	
<i>"United European Gastroenterology Journal" (UEGJ, SAGE, 2018-present)</i>	
<i>"Journal of Clinical Medicine" (MDPI, 2019-present)</i>	
<i>"American Journal of Gastroenterology" (Nature publishing group, 2010-2015 )</i>	
<i>"Digestive Endoscopy" (Wiley, 2012- 2015 )</i>	
<i>"Journal of Gastroenterology" (Springer, 2006-2009)</i>	
<i>"Gastric Cancer" (Springer, 2017-present)</i>	



# SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



*"Journal of Clinical Biochemistry and Nutrition" (JCBN, Nakanishi Printing Co., 2016-present)*

*"Gastroenterology - Annals of Medicine" (Taylor & Francis Group, 2021-present)*

*"Frontiers in non-coding RNA" (Frontiers)*

*"Helicobacter Research (in Japanese)" (Sentan Igaku Co., 2018-present)*

*"Frontiers in Molecular Biosciences" (Frontiers, 2010-present)*

*"Microvascular Communications and Review" (Elsevier, 2006-2016 )*

## MEMBERSHIPS IN MEDICAL AND SCIENTIFIC SOCIETIES:

### International

1994-present The Microcirculatory Society  
 1994-present The Oxygen Society  
 1995-present The American Physiological Society (APS) (Member ID# 8660)  
 1996-present The American Association for the Study of Liver Diseases (AASLD)  
 2004-present The American Gastroenterological Association (AGA)  
 2006-present The American College of Gastroenterology  
 2009-present **Asian Neurogastroenterology and Motility Association (ANMA)**  
 (2012-, **Governing Council member**)

### Domestic

1989-present. The Japanese Society of Internal Medicine  
 1990-present. The Japanese Society of Gastroenterology (2003-, **Executive member**)  
 1991-present. The Japanese Society of Gastroenterological Endoscopy (2006-, **Executive member**)  
 1989-present. **The Japanese Society for Microcirculation (2016-, President)**  
 1990-present. The Japanese Society of Hepatology  
 1992-present. The Japanese Society of Autonomic Nervous System (1998-, **Executive member**)  
 1993-present. The Japanese Society of Ulcer Research (2015-, **Executive Director**)  
 1994-present. The Japanese Society of Helicobacter Research  
 (2014- **Executive Director**, 2017- **Vice President**)  
 1993-present. Society for Free Radical Research, Japan (2001-, **Executive member**)  
 1996-present. The Japanese Society of Digestion and Absorption  
 2000-present. The Japanese Society for Wound Healing  
 2001-present. The Japanese Society of Clinical Chinese Medicine (2013-, **Executive Director**)  
 2002-present. The Japanese Society of Neurogastroenterology (2015-, **Executive Director**)  
 2004-present. The Japanese Gastroenterological Association (2009-, **Executive member**)  
 2007-present. The Japanese Association for Capsule Endoscopy  
 2012-present. The Japanese Association for Cancer Prevention (2017-, **Executive Director**)  
 2013-present. The Japanese Society of Clinical Nutrition  
 2013 **President of the 8th Annual Meeting of Japanese Society of Functional Dyspepsia**  
 2014 **President of International Gastrointestinal Consensus Symposium (IGICS) in JGA**  
 2014-present. Japan Primary Care Association (2018-, **Executive Director**)  
 2015-present. The Japanese Society of Geriatric Gastroenterology (2017-, **Executive Director**)  
 2019 **President of 43rd Annual Meeting for the Japanese Society of Ulcer Research**  
 2019 **President of 21st Annual Meeting for the Japanese Society of Neurogastroenterology**  
 2021 **President of 28th Annual Meeting for the Japan Association of Cancer Prevention (JACP)**

### International committee member:

- The International Society for Diseases of the Esophagus (ISDE), Member of Delphi consensus committee for International guideline (2012-present)
- Rome committee, Rome IV chapter committee member (2012-2016) (**Gastrointestinal Disorders committee**)
- American Gastroenterological Association (AGA) International committee member (2017-2018)
- American Gastroenterological Association (AGA) International subcommittee member (2018-present)

Main Scientific Publications

**BIBLIOGRAPHY** h-index 52



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



### 1.1 Original articles in English (304)

1. Otani K, Watanabe T, Higashimori A, **Suzuki H**, Kamiya T, Shiotani A, Sugimoto M, Nagahara A, Fukudo S, Motoya S, Yamaguchi S, Zhu Q, Chan FKL, Hahm KB, Tablante MC, Prachayakul V, Abdullah M, Ang TL, Murakami K. A Questionnaire-Based Survey on the Impact of the COVID-19 Pandemic on Gastrointestinal Endoscopy in Asia. International Gastrointestinal Consensus Symposium Study Group. **Digestion**. 2022;103(1):7-21. doi: 10.1159/000520287.
2. Mori H, **Suzuki H\***, Matsuzaki J, Kameyama K, Igarashi K, Masaoka T, Kanai T. Development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after *Helicobacter pylori* eradication. **Ann Med**. 2022 Dec;54(1):170-180. doi: 10.1080/07853890.2021.2024875.
3. Toyoshima O, Nishizawa T, Yoshida S, Matsuno T, Odawara N, Toyoshima A, Sakitani K, Watanabe H, Fujishiro M, **Suzuki H**. Consistency between the endoscopic Kyoto classification and pathological updated Sydney system for gastritis: A cross-sectional study. **J Gastroenterol Hepatol**. 2021 Sep 27. doi: 10.1111/jgh.15693.
4. Isomoto H, **Suzuki H**. Experimental and translational research in gastrointestinal endoscopy, the Japan Gastroenterological Endoscopy Society and perspective. **Dig Endosc**. 2021 Sep 24; Online ahead of print. doi:10.1111/den.14129.
5. Nishizawa T, Watanabe H, Yoshida S, Toyoshima A, Kataoka Y, Kanazawa T, Yoshizawa N, Ebinuma H, **Suzuki H**, Toyoshima O. Decreased anti-parietal cell antibody titer in the advanced phase of autoimmune gastritis. **Scand J Gastroenterol**. 2021 Oct 25;1-6. doi: 10.1080/00365521.2021.1994642. Online ahead of print.
6. **Suzuki H\***. Is active exercise effective in preventing metachronous advanced colorectal neoplasm after polypectomy? **Dig Endosc**. 2021 Oct 15. doi: 10.1111/den.14161. Online ahead of print.
7. Fujisawa M, Matushima M, Carreras J, Hirabayashi K, Y Kikuti Y, Ueda T, Kaneko M, Fujimoto R, Sano M, Teramura E, Monma M, Nakae H, Suzuki T, **Suzuki H**, Nakamura N. Whole-genome copy number and immunohistochemical analyses on surgically resected intracholecystic papillary neoplasms. **Pathol Int**. 2021 Dec;71(12):823-830. doi: 10.1111/pin.13177.
8. Imai J, Ichikawa H, Kitamoto S, Golob JL, Kaneko M, Nagata J, Takahashi M, Gilliland MG, Tanaka R, Nagao-Kitamoto H, Hayashi A, Sugihara K, Bishu S, Tsuda S, Ito H, Kojima S, Karakida K, Matsushima M, Suzuki T, Hozumi K, Watanabe N, Giannobile WV, Shirai T, **Suzuki H**, Kamada N. A potential pathogenic association between periodontal disease and Crohn's disease. **JCI Insight**. 2021 Oct 28;6(23):e148543. doi: 10.1172/jci.insight.148543.
9. Omata F, Deshpande GA, **Suzuki H**, Hayashi K, Ishii N, Matoba K, Ohmuro A, Rai F, Takashima M, Fukuda K, Masuda K, Kumakura Y. Long-term cumulative incidence of metachronous advanced colorectal neoplasia after colonoscopy and a novel risk factor: a cohort study. **Eur J Gastroenterol Hepatol**. 2021 Nov 1; 33(11):1341-1347. doi: 10.1097/MEG.0000000000002259.
10. Nishizawa T, Munkjargal M, Ebinuma H, Toyoshima O, **Suzuki H**. Sifloxacin for Third-Line *Helicobacter pylori* Eradication: A Systematic Review. **J Clin Med**. 2021 Jun;10(12):2722. doi: 10.3390/jcm10122722.
11. Okamoto T, **Suzuki H**, Fukuda K. Intraoperative Endoscopy in Transient Adult Jejunojunal Intussusception. **Case Rep Gastrointest Med**. 2021 Jul 12. 2021. doi: 10.1155/2021/3718089.
12. Nishizawa T, Yoshida S, Watanabe H, Toyoshima A, Kataoka Y, Takahashi Y, Kanazawa T, Ebinuma H, **Suzuki H**, Koike K, Toyoshima O. Clue of Diagnosis for Autoimmune Gastritis. **Digestion**. 2021 Jul 1; 102(6):903-910. doi: 10.1159/000516624.
13. Toyoshima O, Nishizawa T, Yoshida S, Aoki T, Nagura F, Sakitani K, Tsuji Y, Nakagawa H, **Suzuki H**, Koike K. Comparison of endoscopic gastritis based on Kyoto classification between diffuse and intestinal gastric cancer. **World J. Gastrointest. Endosc**. 2021 May 16;13(5):125-136.
14. Nishizawa T, Yoshida S, Toyoshima O, Matsuno T, Irokawa M, Arano T, Ebinuma H, **Suzuki H**, Kanai T, Koike K. Risk Factors for Prolonged Hospital Stay after Endoscopy. **Clin Endosc**. 2021 Mar 16. doi: 10.5946/ce.2020.292. Online ahead of print.
15. Okamoto T, **Suzuki H**, Fukuda K. Simultaneous gastric cancer and breast cancer metastases to the stomach with lymph node collision tumor: a case report. **BMC Gastroenterol**. 2021 May 25;21(1):240.
16. Okamoto T, **Suzuki H**, Fukuda K. Gastric linitis plastica due to signet-ring cell carcinoma with Krukenberg tumors diagnosed by endoscopic ultrasound-guided fine-needle aspiration. **Clin J Gastroenterol**. 2021 Mar 19. doi: 10.1007/s12328-021-01387-6.
17. Tsuruya K, Anzai K, Shioyama S, Ito A, Arase Y, Hirose S, Tanaka Y, **Suzuki H**, Kagawa T. A case of hepatitis B virus reactivation following ibrutinib therapy in which the patient remained negative for hepatitis B surface antigens throughout the clinical course. **Hepatol Res**. 2021 Feb;51(2):239-244. doi: 10.1111/hepr.13575.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



18. Fujisawa M, Matsushima M, Ueda T, Kaneko M, Fujimoto R, Sano M, Teramura E, Monma M, Mizukami H, Nakahara F, **Suzuki H**, Suzuki T, Yabe M, Yabe T. Three Cases of Esophageal Cancer Related to Fanconi Anemia. **Intern Med.** 2021 Apr 5. doi: 10.2169/internalmedicine.6926-20.
19. Fujisawa M, Matsushima M, Ueda T, Kaneko M, Fujimoto R, Sano M, Teramura E, Monma M, Mizukami H, Nakahara F, **Suzuki H**, Suzuki T. A Case of Celiac Disease Complicated by Rhabdomyolysis. **Intern Med.** 2021 Jan 15;60(2):217-222. doi: 10.2169/internalmedicine.5358-20.
20. Nishizawa T, Toyoshima O, Kondo R, Sekiba K, Tsuji Y, Ebinuma H, **Suzuki H**, Tanikawa C, Matsuda K, Koike K. The simplified Kyoto classification score is consistent with the ABC method of classification as a grading system for endoscopic gastritis. **J. Clin. Biochem. Nutr.** 2021 Jan;68(1):101-104. doi: 10.3164/jcfn.20-41.
21. Toyoshima O, Nishizawa T, Sekiba K, Matsuno T, Kondo R, Watanabe H, **Suzuki H**, Tanikawa C, Koike K, Matsuda K. A single nucleotide polymorphism in *Prostate Stem Cell Antigen* is associated with endoscopic grading in Kyoto classification of gastritis. **J. Clin. Biochem. Nutr.** 2021 Jan;68(1):73-77.
22. Nadalian B, Yadegar A, Hourri H, Olfatifar M, Shahrokh S, Asadzadeh Aghdai H, **Suzuki H**, Zali MR. Prevalence of the pathobiont adherent-invasive *Escherichia coli* and inflammatory bowel disease: a systematic review and meta-analysis. **J Gastroenterol Hepatol.** 36(4):852-863, 2021. doi: 10.1111/jgh.15260.
23. Morimachi M, Hirabayashi K, Takanashi Y, Kawanishi A, Saika T, Ueyama Y, Nakagohri T, Nakamura N, **Suzuki H**, Kagawa T. Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. **J. Clin. Pathol.** 74(11):741-745, 2021. doi: 10.1136/jclinpath-2020-207002.
24. Mori, H.; Schol, J.; Geeraerts, A.; Huang, I.-H.; Jandee, S.; Gonlachanvit, S.; Tseng, P.-H.; Lu, C.-L.; Kamiya, T.; Kim, N.; Lee, Y.Y.; Kuribayashi, S.; Tack, J.; **Suzuki H.**\* The Impact of COVID-19 on Gastrointestinal Motility Testing in Asia and Europe. **J. Clin. Med.** 2020;9(10):3189. doi : 10.3390/jcm9103189
25. Tack J, Schol J, Geeraerts A, Huang IH, Mori H, Scarpellini E, Sinouque P, Carbone F, Colomier E, Geysen H, Jandee S, Moonen A, Pannemans J, Timmermans L, Van den Houte K, Verbeure W, Wauters L, Bisschops R, Hoffman I, Roelandt P, Rommel N, Simren M, **Suzuki H**, Tornblom H, Verbeke K, Vanuytsel T. A survey on the impact of the COVID-19 pandemic on motility and functional investigations in Europe and considerations for recommencing activities in the early recovery phase. **Neurogastroenterol Motil.** 2020;32(7):e13926. doi: 10.1111/nmo.13926.
26. Tsugawa H, Kabe Y, Kanai A, Sugiura Y, Hida S, Taniguchi S, Takahashi T, Matsui H, Yasukawa Z, Itou H, Takubo K, **Suzuki H**, Honda K, Handa H, Suematsu M. Short-chain fatty acids bind to apoptosis-associated speck-like protein to activate inflammasome complex to prevent Salmonella infection. **PLoS Biol.** 2020 Sep 29;18(9):e3000813. doi: 10.1371/journal.pbio.3000813. eCollection 2020 Sep.
27. Azimirad M, Yadegar A, Gholami F, Shahrokh S, Asadzadeh Aghdai H, Ianiro G, **Suzuki H**, Cammarota G, Zali MR. Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease. **J Inflamm Res.** 2020;13:563-570. doi: 10.2147/JIR.S265520. eCollection 2020.
28. Toyoshima O, Nishizawa T, Yoshida S, Sakaguchi Y, Nakai Y, Watanabe H, **Suzuki H**, Tanikawa C, Matsuda K, Koike K. Endoscopy-based Kyoto classification score of gastritis related to pathological topography of neutrophil activity. **World J Gastroenterol.** 2020 Sep 14;26(34):5146-5155. doi: 10.3748/wjg.v26.i34.5146.
29. Nishizawa T, Sakitani K, **Suzuki H**, Yoshida S, Kataoka Y, Nakai Y, Ebinuma H, Kanai T, Toyoshima O, Koike K. Clinical features of cardiac nodularity-like appearance induced by *Helicobacter pylori* infection. **World J Gastroenterol.** 2020 Sep 21;26(35):5354-5361. doi: 10.3748/wjg.v26.i35.5354.
30. Nishizawa T, Mori K, Yoshida S, Ebinuma H, Toyoshima O, **Suzuki H**\* Additional Mosapride to Proton Pump Inhibitor for Gastroesophageal Reflux Disease: A Meta-Analysis. **J Clin Med.** 2020;9(9):E2705. doi: 10.3390/jcm9092705.
31. Toyoshima O, Nishizawa T, Sakitani K, Yamakawa T, Watanabe H, Yoshida S, Nakai Y, Hata K, Ebinuma H, **Suzuki H**, Koike K. Nodularity-like appearance in the cardia: novel endoscopic findings for *Helicobacter pylori* infection. **Endosc Int Open** 2020 Jun;8(6):E770-E774. doi: 10.1055/a-1136-9890.
32. Toyoshima O, Nishizawa T, Sakitani K, Yamakawa T, Takahashi Y, Kinoshita K, Torii A, Yamada A, **Suzuki H**, Koike K. *Helicobacter pylori* eradication improved the Kyoto classification score on endoscopy. **JGH Open** 2020 May 29;4(5):909-914. doi: 10.1002/jgh3.12360.
33. Nakamura M, Øverby A, Michimae H, Matsui H, Takahashi S, Mabe K, Shimoyama T, Sasaki M, Terao S, Kamada T, Yanaka A, Iwamoto J, Tanabe S, Tari A, Nasu S, **Suzuki H**, Yamagata Murayama S. PCR analysis and specific immunohistochemistry revealing a high prevalence of non-*Helicobacter pylori* *Helicobacters* in *Helicobacter pylori*-negative gastric disease patients in Japan: High susceptibility to an Hp eradication regimen. **Helicobacter.** 2020;25(5):e12700. doi: 10.1111/hel.12700.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



34. Moayedi S, Yadegar A, Balalae S, Yarmohammadi M, Zali MR, **Suzuki H**, Fricker G, Haririan, I. Sugar Codes Conjugated Alginate: An Innovative Platform to Make a Strategic Breakthrough in Simultaneous Prophylaxis of GERD and *Helicobacter pylori* Infection. **Drug Des Devel Ther.** 2020;14:2405-2412. doi: 10.2147/DDDT.S255611.
35. Nakamura M, Kodama Y, Øverby A, Takahashi S, Ohshima K, **Suzuki H**, Murayama SY, Matsui H. Helicobacter heilmannii Infection in Mouse Induced not only Gastric, but Hepatic and Pulmonary MALT Lymphoma: Relation to Substance P. **Curr Pharm Des.** 2020;26(25):3039-3045. doi: 10.2174/138161282666200424163506.
36. Nishizawa T, Sakitani K, **Suzuki H**, Takeuchi M, Takahashi Y, Takeuchi K, Yamakawa T, Yoshida S, Hata K, Ebinuma H, Koike K, Toyoshima O. Adverse events associated with bidirectional endoscopy with midazolam and pethidine. **J Clin. Biochem. Nutr.** 2020 Jan;66(1):78-81. doi: 10.3164/jcfn.19-73.
37. Toyoshima O, Nishizawa T, Sakitani K, Yamakawa T, Yoshida S, Fukagawa K, Hata K, Ishihara S, **Suzuki H**. Colonoscopy using back brace support belt: A randomized, prospective trial. **JGH Open.** 2019;4(3):441-445. doi:10.1002/jgh3.12276.
38. Nishizawa T, Sakitani K, **Suzuki H**, Yamakawa T, Takahashi Y, Yoshida S, Nakai Y, Hata K, Ebinuma H, Koike K, Toyoshima O. Small-caliber endoscopes are more fragile than conventional endoscopes. **Endosc Int Open** 2019;7(12):E1729-E1732. doi: 10.1055/a-1036-6186.
39. Kubosawa Y, Mori H, Kinoshita S, Nakazato Y, Fujimoto A, Kikuchi M, Nishizawa T, Suzuki M, **Suzuki H**. Changes of gastric ulcer bleeding in the metropolitan area of Japan. **World J Gastroenterol.** 2019;25(42):6342-6353. doi: 10.3748/wjg.v25.i42.6342.
40. Hojo M, Nagahara A, Hahm KB, Iwakiri R, Watanabe T, Rani AA, Zhu Q, Chan FKL, Sollano JD, Kamiya T, Yamaguchi S, Motoya S, Fock KM, Fukudo S, Kachintorn U, **Suzuki H**, Murakami K; The International Gastroenterology Consensus Symposium Study Group. Management of Gastroesophageal Reflux Disease in Asian Countries: Results of a Questionnaire Survey. **Digestion** 2020;101(1):66-79. doi: 10.1159/000504749.
41. Farzi, N., Yadegar, A., Sadeghi, A., Asadzadeh Aghdai, H., Marian Smith, S., Raymond, J., **Suzuki, H.**, Zali, M.R. High Prevalence of Antibiotic Resistance in Iranian *Helicobacter pylori* Isolates: Importance of Functional and Mutational Analysis of Resistance Genes and Virulence Genotyping. **J Clin Med.** 2019;8(11). pii:E2004. doi: 10.3390/jcm8112004.
42. Yokoyama, S., Yoshinaga, T., Matsuzaki, J., **Suzuki, H.** A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Teprenone in Patients with Alzheimer's Disease. **J Alzheimers Dis.** 71(4):1187-1199, 2019. doi: 10.3233/JAD-190305.
43. Mori H, **Suzuki, H\***, Matsuzaki J, Masaoka T, Kanai T. 10-Year Trends in *Helicobacter pylori* Eradication Rates by Sifloxacin-Based Third-Line Rescue Therapy. **Digestion** 101(5):644-650, 2020. doi: 10.1159/000501610.
44. Tsugawa H, Kato C, Mori H, Matsuzaki J, Kameyama K, Saya H, Hatakeyama M, Suematsu M, **Suzuki, H\***. Cancer stem-cell marker CD44v9-positive cells arise from *Helicobacter pylori*-infected CAPZA1-overexpressing cells. **Cell. Mol Gastroenterol Hepatol.** 8(3):319-334, 2019. doi: 10.1016/j.jcmgh.2019.05.008. [Epub ahead of print] PubMed PMID: 31146068.
45. Matsuzaki, J., Tsugawa, H., Kashiwazaki, Y., Mori, H., Yamamoto, Y., Kameyama, H., Masaoka, T., Kanai, T., **Suzuki, H\***. Neutrophil-activating protein polymorphism of *Helicobacter pylori* determines the host risk of dyspepsia. **Cell. Mol. Gastroenterol. Hepatol.** 8(2):295-297.e6, 2019. doi: 10.1016/j.jcmgh.2019.05.004. Epub 2019 May 18. PubMed PMID: 31108232.
46. Mori, H., **Suzuki, H.**, Hirai, Y., Okuzawa, A., Kayashima, A., Kubosawa, Y., Kinoshita, S., Fujimoto, A., Nakazato, Y., Nishizawa, T., Kikuchi, M. Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide. **J. Clin. Biochem. Nutri.** 65(1):76-81, 2019. doi: 10.3164/jcfn.18-117. Epub 2019 Jul 1. PubMed PMID: 31379418; PubMed Central PMCID: PMC6667383.
47. Mori H, **Suzuki, H\***, Omata F, Masaoka T, Asaoka D, Kawakami K, Mizuno S, Kurihara N, Nagahara A, Sakaki N, Ito M, Kawamura Y, Suzuki M, Shimada Y, Sasaki H, Matsuhisa T, Torii A, Nishizawa T, Mine T, Ohkusa T, Kawai T, Tokunaga K, Takahashi S. Current status of first- and second-line *Helicobacter pylori* eradication therapy in the metropolitan area: a multicenter study with a large number of patients. **Therap Adv Gastroenterol.** 2019 Jul 4;12:1756284819858511. doi: 10.1177/1756284819858511. eCollection 2019. PubMed PMID: 31320930; PubMed Central PMCID: PMC6611030.
48. Nishizawa, T., Sakitani, K., **Suzuki, H.**, Yamakawa, T., Takahashi, Y., Hata, K., Watanabe, H., Seto, Y., Koike, K., Toyoshima, O. A combination of serum anti-*Helicobacter pylori* antibody titer and Kyoto classification score could provide a more accurate diagnosis of *H. pylori*. **United European Gastroenterol Journal** 7(3):343-348, 2019. doi: 10.1177/2050640619825947. Epub 2019 Jan 15. PubMed PMID: 31019702; PubMed Central PMCID: PMC6466756.
49. Yamaguchi, S., Sasaki, K., Kato, H., Fukudo, S., Iwakiri, R., Kamiya, T., Motoya, S., Murakami, K., Nagahara, A., **Suzuki, H.**, Watanabe, T., Takahashi, S., Chan, FKL, Hahm, KB., Kachintorn, U., Ming, FK., Rani, AA., Sollano, JD., Zhu, Q.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



Questionnaire-based survey on management of ulcerative colitis-associated cancer in East Asian countries. **Digestion** 99(1):86-94, 2019. doi: 10.1159/000494419.

50. Matsuzaki, J., **Suzuki, H.\***, Shimoda, M., Mori, H., Fukuhara, S., Miyoshi, S., Masaoka, T., Iwao, Y., Kanai, T. Clinical and endoscopic findings to assist the early detection of duodenal adenoma and adenocarcinoma. **United European Gastroenterology Journal** 7(2):250-260, 2019. doi: 10.1177/2050640618817689. Epub 2018 Dec 3. PubMed PMID: 31080610; PubMed Central PMCID: PMC6498797.
51. Tsugawa, H., Mori, H., Matsuzaki, J., Sato, A., Saito, Y., Imoto, M., Suematsu, M., **Suzuki, H.\*** CAPZA1 determines the risk of gastric carcinogenesis by inhibiting *Helicobacter pylori* CagA-degraded autophagy. **Autophagy** 15(2):242-258, 2019. doi: 10.1080/15548627.2018.1515530.
52. Nishizawa, T., **Suzuki, H.**, Arita, M., Kataoka, Y., Fukagawa, K., Ohki, D., Hata, K., Uraoka, T., Kanai, T., Yahagi, N., Toyoshima, O. Pethidine dose and female sex as risk factors for nausea after esophagogastroduodenoscopy. **J Clin Biochem Nutr.** 63(3):230-232, 2018. doi: 10.3164/jcbn.18-5.
53. Yokomori, H., Ando, W., Kaneko, F., **Suzuki, H.**, Igarashi, K., Oda, M. Autotaxin and vascular endothelial growth factor receptor-2 and -3 are related to vascular development during the progression of chronic viral hepatitis C. **APMIS.** 126(12):913-921, 2018. doi: 10.1111/apm.12904
54. Miyoshi, S., Tsugawa, H., Matsuzaki, J., Hirata, K., Mori, H., Saya, H., Kanai, T., **Suzuki, H.\*** Inhibiting xCT improves 5-fluorouracil resistance of gastric cancer induced by CD44 variant 9 expression. **Anticancer Res.** 38(11):6163-6170, 2018. doi: 10.21873/anticancer.12969.
55. Masaoka, T., Kameyama, H., Yamane, T., Yamamoto, Y., Takeuchi, H., **Suzuki, H.**, Kitagawa, Y., Kanai, T. Pathophysiology of potassium-competitive acid blocker-refractory gastroesophageal reflux and the potential of potassium-competitive acid blocker test. **J Neurogastroenterol Motil.** 24(4):577-583, 2018. doi:10.5056/jnm18036
56. Toyoshima, O., Nishizawa, T., Sakitani, K., Yamakawa, T., Takahashi, Y., Yamauchi, N., Hata, K., Seto, Y., Koike, K., Watanabe, H., **Suzuki, H.** Serum anti-*Helicobacter pylori* antibody titer and its association with gastric nodularity, atrophy, and age: A cross-sectional study. **World J. Gastroenterol.** 24(35):4061-4068, 2018. doi: 10.3748/wjg.v24.i35.4061
57. Ando, W., Yokomori, H., Kaneko, F., Kaneko, M., Igarashi, K., **Suzuki, H.\*** Serum autotaxin concentrations reflect changes in liver stiffness and fibrosis after antiviral therapy in patients with chronic hepatitis C. **Hepatology Communications** 2(9):1111-1122, 2018. doi: 10.1002/hep4.1230.
58. Toyoshima, O., Nishizawa, T., Arita, M., Kataoka, Y., Sakitani, K., Yoshida, S., Yamashita, H., Hata, K., Watanabe, H., Suzuki, H. *Helicobacter pylori* infection in subjects negative for high titer serum antibody. **World J. Gastroenterol.** 24(13):1419-1428, 2018. doi:10.3748/wjg.v24.i13.1419.
59. Mori, H., **Suzuki, H.\***, Matsuzaki, J., Masaoka, T., Kanai, T. Acquisition of double mutation in *gyrA* caused high resistance to sitafloxacin in *Helicobacter pylori* after unsuccessful eradication with sitafloxacin-containing regimens. **United European Gastroenterology Journal** 6(3):391-397, 2018. doi: https://doi.org/10.1177/2050640617737215.
60. Matsuzaki, J., **Suzuki, H.\***, Togawa, K., Yamane, T., Mori, H., Komori, T., Masaoka, T., Kanai, T. Burden of impaired sleep quality on work productivity in functional dyspepsia. **United European Gastroenterology Journal** 6(3):398-406, 2018. doi: https://doi.org/10.1177/2050640617726466.
61. Fukuhara, S., Masaoka, T., Nishimura, S., Nakamura, M., Matsuzaki, J., Tsugawa, H., Miyoshi, S., Mori, H., Kawase, S., Shibata, S., Okano, H., Kanai, T., **Suzuki, H.\*** Enteric glial dysfunction evoked by apolipoprotein E deficiency contributes to delayed gastric emptying. **Dig. Dis. Sci.** 62(12):3359-3369, 2017. doi:10.1007/s10620-017-4820-7.
62. Tack, J., Corsetti, M., Camilleri, M., Quigley, A., Simren, M., **Suzuki, H.**, Talley, N.J., Tornbloom, H., Van Oudenhove, L. Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. **Gut.** 67(8):1425-1433, 2018. doi:10.1136/gutjnl-2016-312230.
63. Matsuzaki, J., **Suzuki, H.\*** Circulating microRNAs as potential biomarkers to detect transformation of Barrett's oesophagus to oesophageal adenocarcinoma. **BMJ Open Gastroenterol.** 2017;4:e000160. doi: 10.1136/bmjgast-2017-000160.
64. Mori, H., **Suzuki, H.\***, Matsuzaki, J., Masaoka, T., Kanai, T. Antibiotic resistance and *gyrA* mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for *Helicobacter pylori* in penicillin allergic patients. **United European Gastroenterology Journal** 5(6):796-804, 2017. doi: 10.1177/2050640616688995.
65. Nishizawa, T., **Suzuki, H.\***, Fujimoto, A., Kinoshita, H., Yoshida, S., Isomura, Y., Toyoshima, A., Kanai, T., Yahagi, N., Toyoshima, O. Effects of patient age and choice of antisecretory agent on success of eradication therapy for *Helicobacter pylori* infection. **J. Clin. Biochem. Nutri.** 60(3):208-210, 2017. doi: 10.3164/jcbn.16-86.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



66. Mizukami, T., Sugimoto, S., Masaoka, T., **Suzuki, H.**, Kanai, T. Colonic dysmotility and morphological abnormality frequently detected in Japanese patients with irritable bowel syndrome. **Intest. Res.** 15(2):236-243, 2017. doi: 10.5217/ir.2017.15.2.236.
67. Mori, H., **Suzuki, H.**\*, Matsuzaki, J., Taniguchi, K., Shimizu, T., Yamane, T., Masaoka, T., Kanai, T. Gender difference of gastric emptying in healthy volunteers and patients with functional dyspepsia. **Digestion** 95(1):72-78, 2017. doi: 10.1159/000452359.
68. Yoshida, A., Ueno, F., Morizane, T., Joh, T., Kamiya, T., Takahashi, S., Tokunaga, K., Iwakiri, R., Kinoshita, Y., **Suzuki, H.**, Naito, Y., Uchiyama, K., Fukudo, S., Chan, F.K., Halm, K.B., Kachintorn, U., Fock, K.M., Rani, A.A., Syam, A.F., Sollano, J.D., Zhu, Q. International Gastroenterology Consensus Symposium Study Group. Asian Perspectives on Diagnostic and Therapeutic Strategies in Inflammatory Bowel Disease: Report and Analysis of a Survey with Questionnaires. **Digestion** 95(1):79-88, 2017 doi:10.1159/000453007.
69. Øverby, A., Murayama, S.Y., Michimae, H., **Suzuki, H.**, Suzuki, M., Serizawa, H., Tamura, R., Nakamura, S., Takahashi, S., Nakamura, M. Prevalence of gastric Non-*Helicobacter pylori*-*Helicobacters* in Japanese patients with gastric disease. **Digestion** 95(1):61-66, 2017. doi: 10.1159/000452400.
70. Nishizawa, T., **Suzuki, H.**\*, Sakitani, K., Yamashita, H., Yoshida, S., Hata, K., Kanazawa, T., Fujiwara, N., Kanai, T., Yahagi, N., Toyoshima, O. Family history is an independent risk factor for the progression of gastric atrophy among patients with *Helicobacter pylori* infection. **United European Gastroenterology Journal** 5(1):32-36, 2017. doi: 10.1177/2050640616642341.
71. Nakano, M., Yahiro, K., Yamasaki, E., Kurazono, H., Akada, J., Yamaoka, Y., Niidome, T., Hatakeyama, M., **Suzuki, H.**, Yamamoto, T., Moss, J., Isomoto, H., Hirayama, T. *Helicobacter pylori* VacA, acting through receptor protein tyrosine phosphatase  $\alpha$ , is crucial for CagA phosphorylation in human duodenum carcinoma cell line AZ-521. **Dis Model Mech.** 9(12):1473-1481, 2016. doi: 10.1242/dmm.025361.
72. Nishizawa, T., **Suzuki, H.**\*, Arano, T., Yoshida, S., Yamashita, H., Hata, K., Kanai, T., Yahagi, N., Toyoshima, O. Characteristics of gastric cancer detected within 1 year after successful eradication in *Helicobacter pylori*. **J. Clin. Biochem. Nutri.** 59(3):226-230, 2016. doi:10.3164/jcfn.16-43.
73. Horibe, M., Kaneko, T., Yokogawa, N., Yokota, T., Okawa, O., Nakatani, Y., Ogura, Y., Matsuzaki, J., Iwasaki, E., Hosoe, N., Masaoka, T., Inadomi, J.M., **Suzuki, H.**, Kanai, T., Namiki, S. A simple scoring system to assess the need for an endoscopic intervention in suspected upper gastrointestinal bleeding: A prospective cohort study. **Dig. Liver Dis.** 48(10):1180-6, 2016. doi: 10.1016/j.dld.2016.07.009. (IF: 3.061)
74. Lee, S-Y., Masaoka, T., Han, H-S., Matsuzaki, J., Hong, M-J., Fukuhara, S., Choi, H-S, **Suzuki, H.**\* A prospective study on symptom generation according to spicy food intake and TRPV1 genotypes in functional dyspepsia patients. **Neurogastroenterol. Motil.** 28(9):1401-1408, 2016. doi: 10.1111/nmo.12841.
75. Matsuzaki, J., **Suzuki, H.**\*, Masaoka, T., Tanaka, K., Mori, H., Kanai, T. Influence of regular exercise on gastric emptying in healthy men: a pilot study. **J. Clin. Biochem. Nutri.** 59 (2):130-133, 2016. doi:10.3164/jcfn.16-29.
76. Mori, H., **Suzuki, H.**\*, Matsuzaki, J., Tsugawa, H., Fukuhara, S., Miyoshi, S., Hirata, K., Seino, T., Matsushita, M., Nishizawa, T., Masaoka, T., Kanai, T. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for *Helicobacter pylori* eradication: a pilot study. **United European Gastroenterology Journal** 4(3):380-387, 2016. doi:10.1177/2050640615618043.
77. Matsuzaki, J., Hayashi, R., Arakawa, T., Ueno, F., Kinoshita, Y., Joh, T., Takahashi, S., Naito, Y., Fukudo, S., Chan, F.K., Halm, K.B., Kachintorn, U., Fock, K.M., Syam, A.F., Rani, A.A., Sollano, J.D., Zhu, Q., Fujiwara, Y., Kubota, E., Kataoka, H., Tokunaga, K., Uchiyama, K., **Suzuki, H.**\*; IGICS (The International Gastroenterology Consensus Symposium) Study Group. Questionnaire-Based Survey on Diagnostic and Therapeutic Endoscopies and *H. pylori* Eradication for Elderly Patients in East Asian Countries. **Digestion** 93(1):93-102, 2016.doi:10.1159/000440741.
78. Mori, H., **Suzuki, H.**\*, Matsuzaki, J., Tsugawa, H., Fukuhara, S., Miyoshi, S., Hirata, K., Seino, T., Matsushita, M., Masaoka, T., Kanai, T. Efficacy of 10-day sitafloxacin-containing third-line rescue therapies for *Helicobacter pylori* strains containing the *gyrA* mutation. **Helicobacter** 21(4):286-94, 2016. doi:10.1111/hel.12286.
79. Nishizawa, T., Uraoka, T., Sagara, S., **Suzuki, H.**, Akimoto, T., Kanai, T., Yahagi, N. Endoscopic slip knot clip suturing method: An ex vivo feasibility study (with video). **Gastrointest. Endosc.** 83(2):447-450, 2016.doi:10.1016/j.gie.2015.09.007.
80. Togawa, K., Matsuzaki, J., Kobayakawa, M., Fukushima, Y., Suzuki, F., Kasugai, K., Nishizawa, T., Naito, Y., Hayakawa, T., Kamiya, T., Andoh, T., Yoshida, H., Tokura, Y., Nagata, H., Mori, M., Kato, K., Hosoda, H., Takebayashi, T., Miura, S., Uemura, N., Joh, T., Hibi, T., **Suzuki, H.**\* Association of baseline plasma des-acyl ghrelin level with the response to



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



- rikunshito in patients with functional dyspepsia. **J. Gastroenterol. Hepatol.** 31(2):334-341, 2016.doi:10.1111/jgh.13074.
81. Saito, Y., Serizawa, H., Kato, Y., Nakano, M., Nakamura, M., Saito, H., **Suzuki, H.**, Kanai, T. First-line eradication for *Helicobacter pylori*-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. **World J. Gastroenterol.** 21(48):13548-54, 2015.doi:10.3748/wjg.v21.i48.13548.
  82. Akazawa, Y., Isomoto, H., Matsuda, K., Matsushima, K., Kido, Y., Yamaguchi, N., Ohnita, K., Takeshima, F., Kondo, H., Tsugawa, H., **Suzuki, H.**, Hirayama, T., Nakao, K., Nakashima, M. Association of BH3-only protein Bim with the degree of gastritis and its localization in the mitochondria of inflammatory cells of *Helicobacter pylori*-infected mucosa. **Int. J. Med. Microbiol.** 305(6):553-62, 2015.
  83. Matsuzaki, J., **Suzuki, H.\***, Kobayakawa, M., Inadomi, J.M., Takayama, M., Makino, K., Iwao, Y., Sugino, Y., Kanai, T. Association of visceral fat area, smoking and alcohol consumption with reflux esophagitis and Barrett's esophagus in Japan. **PLoS One** 10(7):e0133865, 2015.doi:10.1371/journal.pone.0133865.
  84. Nishizawa, T., Uraoka, T., **Suzuki, H.**, Goto, O., Ochiai, Y., Fujimoto, A., Maehata, T., Kanai, T., Yahagi, N. New Endoscopic Suturing Method:slip knot clip suturing. **Gastrointest. Endosc.** 82(3):570-571, 2015.doi:10.1016/j.gie.2015.04.012.
  85. Tsugawa, T., Mori, H., Matsuzaki, J., Masaoka, T., Hirayama, T., Nagasawa, H., Sakakibara, Y., Suematsu, M., **Suzuki, H.\*** Nordihydroguaiaretic acid disrupts the antioxidant ability of *Helicobacter pylori* through the repression of SodB activity *in vitro*. **Biomed. Res. Int.** 2015: ID 734548, 8 pages, 2015.doi:10.1155/2015/734548.
  86. Nishizawa, T., Uraoka, T., Ochiai, Y., **Suzuki, H.**, Goto, O., Fujimoto, A., Maehata, T., Kanai, T., Yahagi, N. The "two-sword fencing" technique in endoscopic submucosal dissection. **Clin. Endosc.** 48(1):85-86, 2015. doi:10.5946/ce.2015.48.1.85.
  87. Fukudo, S., .Hahm, KB, Zhu, Q., Sollano, JD., Rani, AA., Syam, AF., Kachintorn, U., **Suzuki, H.**, Kamiya, T., Joh, T., Uchiyama, K., Naito, Y., Takahashi, S., Kinoshita, Y., Ueno, F., Yamagami, H., Chan, FK., Fock, KM., Arakawa, T. Survey of clinical practice for irritable bowel syndrome in East asian countries. **Digestion** 91(1):99-109, 2015.doi:10.1159/000369078.
  88. Nishizawa, T., Maekawa, T., Watanabe, N., Harada, N., Hosoda, Y., Yoshinaga, M., Yoshio, T., Ohta, H., Inoue, S., Toyokawa, T., Yamashita, H., Saito, H., Kuwai, T., Katayama, S., Masuda, E., Miyabayashi, H., Kimura, T., Nishizawa, Y., Takahashi, M., **Suzuki, H.\*** Clarithromycin versus metronidazole as first-line *Helicobacter pylori* eradication: A multicenter, prospective, randomized controlled study in Japan. **J. Clin. Gastroenterol.** 49(6):468-71, 2015.doi:10.1097/MCG.000000000000165.
  89. Hirata, K., Hosoe, N., Imaeda, H., Naganuma, M., Murata, H., Ueno, M., **Suzuki, H.**, Ogata, H., Kanai, T. Obscure Gastrointestinal Bleeding: Resection of a Pyogenic Granuloma of the Ileum via Double-balloon Enteroscopy. **Clin. J. Gastroenterol.** 7(5):397-401, 2014.doi:10.1007/s12328-014-0524-0.
  90. Imaeda, H., Hosoe, N., Kashiwagi, K., Ida, Y., Nakamura, R., **Suzuki, H.**, Saito, Y., Yahagi, N., Iwao, Y., Kitagawa, Y., Hibi, T., Ogata, H., Kanai, T. Surveillance using trimodal imaging endoscopy after endoscopic submucosal dissection for superficial gastric neoplasia. **World J. Gastroenterol.** 20(43):16311-7, 2014.doi:10.3748/wjg.v20.i43.16311.
  91. Kawai, T., Takahashi, S., **Suzuki, H.**, Sasaki, H., Nagahara, A., Asaoka, D., Matsuhisa, T., Masaoka, T., Nishizawa, T., Suzuki, M., Ito, M., Kurihara, N., Omata, F., Mizuno, S., Torii, A., Kawakami, K., Ohkusa, T., Tokunaga, K., Mine, T., Sakaki, N. Changes in the first line *Helicobacter pylori* eradication rates using the triple therapy – a multicenter study in the Tokyo metropolitan area (Tokyo *Helicobacter pylori* study group). **J. Gastroenterol. Hepatol.** 29(S4):29-32, 2014.doi:10.1111/jgh.12796.
  92. Fukuhara, S., Matsuzaki, J., Tsugawa, H., Masaoka, T., Miyoshi, S., Mori, H., Fukushima, Y., Yasui, M., Kanai, T., **Suzuki, H.\*** Musosal expression of aquaporin-4 in the stomach of histamine type 2 receptor knockout mice and *Helicobacter pylori*-infected mice. **J. Gastroenterol. Hepatol.** 29(S4):53-59, 2014.doi:10.1111/jgh.12771.
  93. Nakamura, M., Takahashi, T., Matsui, H., Baniwa, Y., Takahashi, S., Murayama, S.Y., Serizawa, H., **Suzuki, H.**, Hibi, T. Alteration of angiogenesis in *Helicobacter-heimannii*-induced MALT lymphoma: interaction with c-Met and HGF. **J. Gastroenterol. Hepatol.** 29(S4):70-76, 2014.doi:10.1111/jgh.12776.
  94. **Suzuki, H.\***, Matsuzaki, J., Fukushima, Y., Suzaki, F., Kasugai, K., Nishizawa, T., Naito, Y., Hayakawa, T., Kamiya, T., Andoh, T., Yoshida, H., Tokura, Y., Nagata, H., Kobayakawa, M., Mori, M., Kato, K., Hosoda, H., Takabayashi, T., Miura, S., Uemura, N., Joh, T., Hibi, T., Tack, J. Randomised clinical trial: rikkunshito in the treatment of functional dyspepsia – a multi-centre, double-blind, randomised, placebo-controlled study. **Neurogastroenterol. Motil.** 26(7):950-961, 2014.doi:10.1111/nmo.12348.
  95. Nishizawa, T., Uraoka, T., **Suzuki, H.**, Ochiai, Y., Goto, O., Fujimoto, A., Maehata, T., Kanai, T., Yahagi, N. Control of tip deflection by right pinkie shaft grip: right pinkie maneuver. **Gastrointest. Endosc.** 80(6):1208, 2014.doi:10.1016/j.gie.2014.08.016.





# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



96. Nishizawa, T., Uraoka, T., **Suzuki, H.**, Kinoshita, S., Ochiai, Y., Goto, O., Fujimoto, A., Kanai, T., Yahagi, N. Control of the treatment device for endoscope by left hand: two fingers method. **Gastrointest. Endosc.** 80(6):1206-1207, 2014. doi:10.1016/j.gie.2014.07.063.
97. **Suzuki, H.\*** Matsuzaki, J., Masaoka, T., Inadomi, J.M. Greater loss of productivity among Japanese workers with gastroesophageal reflux disease (GERD) symptoms that persist vs resolve on medical therapy. **Neurogastroenterol. Motil.** 26(6):764-771, 2014. doi:10.1111/nmo.12319.
98. Kurotsu, S., Tanaka, K., Niino, T., Asano, T., Sugizaki, T., Azuma, A., **Suzuki, H.**, Mizushima, T. Ameliorative effect of mepenzolate bromide against pulmonary fibrosis. **J. Pharmacol. Exp. Ther.** 350(1):79-88, 2014. doi:10.1124/jpet.114.213009.
99. Tanaka, K., Kurotsu, S., Asano, T., Yamakawa, N., Kobayashi, D., Yamashita, Y., Yamazaki, H., Ishihara, T., Watanabe, H., Maruyama, T., **Suzuki, H.**, Mizushima, T. Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease. **Sci. Rep.** 4:4510, 2014. doi:10.1038/srep04510.
100. Hida, N., Nakamura, S., Hahm, K-B., Sollano, J.D., Zhu, Q., Rani, A.A., Syam, A.F., Kachintorn, U., Ueno, F., Joh, T., Naito, Y., **Suzuki, H.**, Takahashi, S., Fukudo, S., Fujiwara, Y., Kinoshita, Y., Uchiyama, K., Yamaguchi, Y., Yoshida, A., Arakawa, T., Matsumoto, T., The IGICS Study Group. A questionnaire-based survey on the diagnosis and management of inflammatory bowel disease in East Asian countries in 2012. **Digestion** 89(1):88-103, 2014. doi:10.1159/000356706.
101. Nakamura, M., Takahashi, T., Matsui, H., Takahashi, S., Murayama, SY., **Suzuki, H.**, Tsuchimoto, K. New pharmaceutical treatment of gastric MALT lymphoma: anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib. **Curr. Pharm. Des.** 20(7):1097-1103, 2014.
102. **Suzuki, H.\*** Kusunoki, H., Kamiya, T., Futagami, S., Yamaguchi, Y., Nishizawa, T., Iwasaki, E., Matsuzaki, J., Takahashi, S., Sakamoto, C., Haruma, K., Joh, T., Asakura, K., Hibi, T. Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study) : a multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial. **United European Gastroenterology Journal** 1(6):445-452, 2013. doi:10.1177/2050640613510904.
103. Matsuzaki, J., **Suzuki, H.\***, Tsugawa, H., Watanabe, M., Hossain, S., Arai, E., Saito, Y., Sekine, S., Akaike, T., Kanai, Y., Mukaisho, K.I., Auwerx, J., Hibi, T. Bile acids increase levels of *microRNAs 221 and 222*, leading to degradation of CDX2 during esophageal carcinogenesis. **Gastroenterology** 145(6):1300-11, 2013. doi:10.10531/j.gastro.2013.08.00818.187.
104. Hirata, K., **Suzuki, H.\***, Imaeda, H., Matsuzaki, J., Tsugawa, H., Nagano, O., Asakura, K., Saya, H., Hibi, T. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. **Br. J. Cancer** 109(2):379-86, 2013. doi:10.1038/bjc.2013.314.
105. Nishizawa, T., **Suzuki, H.\***, Takahashi, M., Suzuki, M., Hibi, T. Delay of second-line eradication therapy for *H. pylori* can increase eradication failure. **J. Gastroenterol. Hepatol.** 28(10):1608-1610, 2013. doi:10.1111/jgh.12281.
106. **Suzuki, H.\*** Matsuzaki, J., Okada, S., Fukuhara, S., Hirata, K., Hibi, T. Validation of the GerdQ questionnaire for the management of gastroesophageal reflux disease in Japan. **United European Gastroenterology Journal** 1(3):175-183, 2013. doi:10.1177/2050640613485238.
107. Mogami, S., **Suzuki, H.\***, Tsugawa, H., Fukuhara, S., Hibi, T. Impaired heme oxygenase-1 induction in the gastric antrum induces disruption of the interstitial cells of Cajal network in a rat model of streptozotocin-induced diabetes. **Neurogastroenterol. Motil.** 25(7):609-e465, 2013. doi:10.1111/nmo.12122.
108. Takahashi, T., **Suzuki, H.\***, Imai, T., Shibata, S., Tabuchi, Y., Tsuchimoto, K., Okano, H., Hibi, T. Musashi-1 post-transcriptionally enhances phosphotyrosine-binding domain-containing m-Numb protein expression in regenerating gastric mucosa. **PLoS One** 8(1): e53540, 2013. doi:10.1371/journal.pone.0053540.
109. Matsuzaki, J., **Suzuki, H.\***, Okuda, S., Tanimoto, A., Asakura, K., Fukuhara, S., Okada, S., Hirata, K., Mori, H., Masaoka, T., Higuchi, H., Hozawa, S., Kuribayashi, S., Takebayashi, T., Hibi, T. Biliary findings assist in predicting enlargement of intraductal papillary mucinous neoplasms of the pancreas. **Clin. Gastroenterol. Hepatol.** 11(5):548-554, 2013. doi:10.1016/j.cgh.2012.11.027.
110. Hirata, K., **Suzuki, H.\***, Matsuzaki, J., Masaoka, M., Saito, Y., Nishizawa, T., Iwasaki, E., Fukuhara, S., Okada, S., Hibi, T. Improvement of reflux symptom related quality of life after *Helicobacter pylori* eradication therapy. **J. Clin. Biochem. Nutri.** 52(2):172-178, 2013. doi:0.3164/jcfn.12-107.
111. Nishizawa, T., **Suzuki, H.\***, Takahashi, M., Kaneko, H., Suzuki, M., Hibi, T. Effect of ursodeoxycholic acid and endoscopic sphincterotomy in long-term stenting for common bile duct stones. **J. Gastroenterol. Hepatol.** 28(1):63-7, 2013. doi:10.1111/jgh.12012.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



112. Tanaka, K., Ishihara, T., Sugizaki, T., Kobayashi D., Yamashita, Y., Tahara, K., Yamakawa, N., Iijima, K., Mogushi, K., Tanaka, H., Sato, K., **Suzuki, H.**, Mizushima, T. Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease. **Nature Commun.** Nov 5;4, 2013.doi:10.138/ncomms3686.
113. Asaoka, D., Nagahara, A., Matsuhisa, T., Takahashi, S., Tokunaga, K., Kawai, T., **Suzuki, H.**, Suzuki, M., Nishizawa, T., Kurihara, N., Ito, M., Sasaki, H., Omata, F., Mizuno, S., Torii, A., Ohkusa, T., Mine, T., Sakaki, N. Trends of second-line eradication therapy for *Helicobacter pylori* in Japan: A Multicenter Study in the Tokyo Metropolitan Area. **Helicobacter** 18(6):468-472, 2013.doi:10.1111/hel.12063.
114. Mizuno, S., Yamagishi, Y., Ebinuma, H., Nakamoto, N., Katahira, M., Sasaki, A., Sakamoto, M., **Suzuki, H.**, Kanai, T., Hibi, T. Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. **Clin. J. Gastroenterol.** 6(2):188-192, 2013.doi:10.1007/s12328-013-0371-4.
115. Hirano, Y., Takeuchi, H., Oyama, T., Saikawa, Y., Niihara, M., Sako, H., Omagari, K., Nishi, T., **Suzuki, H.**, Hibi, T., Kitagawa, Y. Minimally invasive surgery for esophageal epiphrenic diverticulum – the results of our experience and 133 patients in 25 published series and our experience. **Surgery Today** 43(1):1-7, 2013.doi:10.1007/s00595-012-0386-3.
116. Saito, Y., **Suzuki, H.\***, Imaeda, H., Matsuzaki, J., Hirata, K., Tsugawa, H., Hibino, S., Kanai, Y., Saito, H., Hibi, T. The tumor suppressor *microRNA-29c* is downregulated and restored by celecoxib in human gastric cancer cells. **Int. J. Cancer** 132(8):1751-60, 2013.doi:10.1002/ijc.27862.
117. Nakashita, M., **Suzuki, H.\***, Miura, S., Taki, T., Uehara, K., Mizushima, T., Nagata, H., Hibi, T. Attenuation of acetic acid-induced gastric ulcer formation in rats by glucosylceramide synthase inhibitors. **Dig. Dis. Sci.** 58(2):354-62, 2013.doi:10.1007/s10620-012-2350-x.
118. Tsugawa, H., **Suzuki, H.\***, Saya, H., Hatakeyama, M., Hirayama, T., Hirata, K., Nagano, O., Matsuzaki, J., Hibi, T. Reactive oxygen species-induced autophagic degradation of *Helicobacter pylori* CagA is specifically suppressed in cancer stem-like cells. **Cell Host Microbe** 12(6):764-777, 2012.doi:10.1016/j.chom.2012.10.014.
119. Iwasaki, E., **Suzuki, H.\***, Mogami, S., Hibi, T. Enhanced gastric ghrelin induced c-kit protein expression in rats with gastric outlet obstruction. **Dig. Dis. Sci.** 57(12):3308-3309, 2012.doi:10.1007/s10620-012-2451-6.
120. Saito, Y., **Suzuki, H.\***, Tsugawa, H., Imaeda, H., Matsuzaki, J., Hirata, K., Hosoe, N., Nakamura, M., Hosoe, N., Saito, H., Hibi, T. Overexpression of *miR-142-5p* and *miR-155* in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to *Helicobacter pylori* eradication. **PLoS One** 7(11):e47396, 2012.doi:10.1371/journal.pone.0047396.
121. Saito, Y., **Suzuki, H.\***, Taya, T., Nishizawa, M., Tsugawa, H., Matsuzaki, J., Hirata, K., Saito, H., Hibi, T. Development of a novel *microRNA* promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs. **Biochem. Biophys. Res. Com.** 426(1):33-37, 2012.doi:10.1016/j.bbrc.2012.08.012.
122. Nakamizo, H., **Suzuki, H.\***, Miura, S., Mogami, S., Kishikawa, H., Yoshida, H., Matsui, H., Hibi, T. Transmural pressure loading enhances gastric mucosal proliferation. **Dig. Dis. Sci.** 57(10):2545-2554, 2012.doi:10.1007/s10620-012-2208-2.
123. Matsuzaki, J., **Suzuki, H.\***, Fukushima, Y., Hirata, K., Fukuhara, S., Okada, S., Hibi, T. High frequency of overlap between functional dyspepsia and overactive bladder. **Neurogastroenterol. Motil.** 24(9):821-7, 2012.doi:10.1111/j.1365-2982.2012.01939X.
124. Fukushima, Y., **Suzuki, H.\***, Matsuzaki, J., Kiyosue, A., Hibi, T. Efficacy of solifenacin on irritable bowel syndrome with diarrhea (IBS-D): open-label prospective pilot trial. **J. Neurogastroenterol. Motil.** 18(3): 317-323, 2012.doi:10.5056/jnm.2012.18.3.317.
125. Nishizawa, T., **Suzuki, H.\***, Maekawa, T., Harada, N., Toyokawa, T., Kuwai, T., Ohara, M., Suzuki, T., Kawanishi, M., Noguchi, K., Yoshio, T., Katsushima, S., Tsuruta, H., Masuda, E., Tanaka, M., Katayama, S., Kawamura, N., Nishizawa, Y., Hibi, T., Takahashi, M. Dual therapy for third-line *H. pylori* eradication and urea breath test prediction. **World J. Gastroenterol.** 18(21):2735-2738, 2012.doi:10.3748/wjg.v18.i21.2735.
126. Tsugawa, H., **Suzuki, H.\***, Matsuzaki, J., Hirata, K., Hibi, T. FecA1, a bacterial iron transporter, determines the survival of *Helicobacter pylori* in the stomach. **Free Radic. Biol. Med.** 52(6):1003-1010, 2012.doi:10.1016/j.freeradbiomed.2011.12.011.
127. Matsuzaki, J., **Suzuki, H.\***, Asakura, K., Fukushima, Y., Inadomi, J.M., Takebayashi, T., Hibi, T. Classification of functional dyspepsia based on concomitant bowel symptoms. **Neurogastroenterol. Motil.** 24(4):325-e164, 2012. doi:10.1111/j.1365-2982-2011.01859.x.
128. Kobayashi, S., Okamura, Y., **Suzuki, H.\***, Taniki, N., Uehara, J., Ojio, K., Teramoto, K., Kurinoki, M., Chigusa, Y., Shiwaku, K., Hibi, T. Capsule endoscopy assists in the complete deworming of parasites. **J. Gastroenterol. Hepatol.** 27:1253, 2012.doi:10.1111/j.1440-1746.2012.07154.x.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



129. Matsuzaki, J., **Suzuki, H.\***, Nishizawa, T., Hirata, K., Tsugawa, H., Saito, Y., Okada, S., Fukuhara, S., Hibi, T. Efficacy of sitafloxacin-based rescue therapy for *Helicobacter pylori* after failures of first- and second-line therapies. **Antimicrob. Agent Chemother.** 56(3):1643-45, 2012.doi:10.1128/AAC.05941-11.
130. Nishizawa, T., **Suzuki, H.\***, Suzuki, M., Takahashi, M., Hibi, T. PPI-amoxicillin-clarithromycin versus PPI-amoxicillin-metronidazole as first-line *Helicobacter pylori* eradication therapy. **J. Clin. Biochem. Nutri.** 51(2):114-6, 2012.doi:10.3164/jcfn.D-11-00029R1.
131. Mogami, S., **Suzuki, H.\***, Fukuhara, S., Matsuzaki, J., Kangawa, K., Hibi, T. Reduced ghrelin production induced anorexia after rat gastric ischemia and reperfusion. **Am. J. Physiol., Gastrointest. Liver Physiol.** 302(3):G359-64, 2012. doi:10.1152/ajpgi.00297.2011.
132. Iwasaki, E., **Suzuki, H.\***, Masaoka, T., Nishizawa, T., Hosoda, H., Kangawa, K., Hibi, T. Enhanced gastric ghrelin production and secretion in rats with gastric outlet obstruction. **Dig. Dis. Sci.** 57(4):858-864, 2012.doi:10.1007/s10620-011-1953-y.
133. Fujii, Y., Yoshihashi, K., **Suzuki, H.**, Tsutsumi, S., Mutoh, H., Maeda, S., Aburatani, H., Hatakeyama, M. CDX1 confers intestinal phenotype on gastric epithelial cells via induction of stemness-associated reprogramming factors SALL4 and KLF5. **Proc. Natl. Acad. Sci. USA** 109(50):20584-20589, 2012.doi:10.1073/pnas.1208651109.
134. Suemasu, S., Yamakawa, N., Ishihara, T., Asano, T., Tahara, K., Tanaka, K., Matsui, H., Okamoto, Y., Otsuka, M., Takeuchi, K., **Suzuki, H.**, Mizushima, T. Identification of unique NSAID, fluoro-loxoprofen with gastroprotective activity. **Biochem. Pharmacol.** 84(11):1470-81, 2012.doi:10.1016/j.bcp.2012.09.016.
135. Yahiro, K., Satoh, M., Nakano, M., Hisatune, J., Isomoto, H., Sap, J., **Suzuki, H.**, Nomura, F., Noda, M., Moss, J., Hirayama, T. Low-density lipoprotein receptor-related protein-1 (LRP-1) mediates autophagy and apoptosis caused by *Helicobacter pylori* VacA. **J. Biol. Chem.** 287(37):31104-15, 2012.doi:10.1074/jbc.M112.387498.
136. Ishimura, N., Amano, Y., Sollano, J.D., Zhu, Q., Kachintorn, U., Rani, A.A., Hahm, K-B., Takahashi, S., Arakawa, T., Joh, T., Matsumoto, T., Naito, Y., **Suzuki, H.**, Ueno, F., Fukudo, S., Fujiwara, Y., Kamiya, T., Uchiyama, K., Kinoshita, Y., The IGICS Study Group. Questionnaire-based survey conducted in 2011 concerning endoscopic management of Barrett's esophagus in East Asian countries. **Digestion** 86(2):136-146, 2012.doi:10.1159/000339778.
137. Naito, Y., Uchiyama, K., Kinoshita, Y., Fukudo, S., Joh, T., **Suzuki, H.**, Takahashi, S., Ueno, F., Fujiwara, Y., Arakawa, T., Matsumoto, T., Hahm, K.B., Kachintorn, U., Syam A.F., Rani, A.A., Sollano, J.D., Zhu, Q. A Questionnaire-Based Survey on Screening for gastric and colorectal cancer by physicians in East Asian countries in 2010. **Digestion** 86(2):94-106, 2012.doi:10.1159/000339342.
138. Asano, T., Tanaka, K., Suemasu, S., Ishihara, T., Tahara, K., Suzuki, T., **Suzuki, H.**, Fukudo, S., Mizushima, T. Effects of (1,3-1,6)-D-glucan on irritable bowel syndrome-related colonic hypersensitivity. **Biochem. Biophys. Res. Com.** 420(2):444-9, 2012.doi:10.1016/j.bbrc.2012.03.015.
139. Nishizawa, T., **Suzuki, H.\***, Matsuzaki, J., Muraoka, H., Tsugawa, H., Hirata, K., Hibi, T. *Helicobacter pylori* resistance to rifabutin in the last 7 years. **Antimicrob. Agent Chemother.** 55(11):5374-5, 2011.doi:10.1128/AAC.05437-11.
140. Nishizawa, T., **Suzuki, H.\***, Takahashi, M., Kaneko, H., Fujiyama, Y., Komatsu, H., Nagumo, H., Tanaka, S., Hibi, T. Trainee participation during colonoscopy adversely affects the rates of polyp and adenoma detection. **Digestion** 84(3):245-246, 2011.doi:10.1159/000330736.
141. Nishizawa, T., **Suzuki, H.\***, Tsugawa, H., Muraoka, H., Matsuzaki, J., Hirata, K., Ikeda, F., Takahashi, M., Hibi, T. Enhancement of amoxicillin resistance after unsuccessful *Helicobacter pylori* eradication. **Antimicrob. Agent Chemother.** 55(6):3012-3014, 2011.doi:10.1128/AAC.00188-11.
142. Matsuzaki, J., **Suzuki, H.\***, Asakura, K., Saito, Y., Hirata, K., Takebayashi, T., Hibi, T. Etiological difference between ultrashort-segment Barrett's esophagus and short-segment Barrett's esophagus in Japan. **J. Gastroenterol.** 46(3):332-8, 2011.doi:10.1007/s00535-010-353-y.
143. Tsugawa, H., **Suzuki, H.\***, Muraoka, H., Ikeda, F., Hirata, K., Matsuzaki, J., Saito, Y., Hibi, T. Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in *Helicobacter pylori*. **Biochem. Biophys. Res. Com.** 404(2):656-60, 2011.doi:10.1016/j.bbrc.2010.12.03.
144. Saito, Y., **Suzuki, H.\***, Tsugawa, H., Suzuki, S., Matsuzaki, J., Hirata, K., Hibi, T. Dysfunctional gastric emptying with downregulation of muscle-specific microRNAs in *Helicobacter pylori*-infected mice. **Gastroenterology** 140(1):189-198, 2011.doi:10.1053/j.gastro.2010.08.044.
145. Tsugawa, H., **Suzuki, H.\***, Satoh, K., Hirata, K., Matsuzaki, J., Saito, Y., Suematsu, M., Hibi, T. Two amino acids mutation of Ferric uptake regulator (Fur) determines *Helicobacter pylori* resistance to metronidazole. **Antioxid. Redox Signal.** 14(1):15-23, 2011.doi:10.189/ars.2010.3146.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



146. Imaeda, H., Hosoe, N., **Suzuki, H.**, Saito, Y., Ida, Y., Nakamura, R., Iwao, Y., Ogata, H., Hibi, T. Effect of lansoprazole versus roxatidine on prevention of bleeding and ulcer healing after endoscopic submucosal dissection for superficial gastric neoplasia. **J. Gastroenterol.** 46(11):1267-72, 2011.doi:10.1007/s00535-011-0447-1.
147. den Hoed, C.M., de Vries, A.C., Mensink, P.B., Dierikx, C.M., **Suzuki, H.**, Capelle, L., vanDekken, H., Ouwendijk, R., Kuipers, E.J. Bovine antibody-based oral immunotherapy for reduction of intragastric *Helicobacter pylori* colonization: a randomized clinical trial. **Can. J. Gastroenterol.** 25(4):207-13, 2011.doi:10.1155/2011/672093.
148. Matsuzaki, J., **Suzuki, H.\***, Iwasaki, E., Yokoyama, H., Sugino, Y., Hibi, T. Serum lipid levels are positively associated with non-erosive reflux disease, but not with functional heartburn. **Neurogastroenterol. Motil.** 22(9):965-970, e251, 2010.doi:10.1111/j.1365-2982.2010.01518.x.
149. Matsuzaki, J., **Suzuki, H.\***, Minegishi, Y., Sugai, E., Tsugawa, H., Yasui, M., Hibi, T. Acid suppression by proton pump inhibitors enhances aquaporin-4 and kcnq1 expression in gastric fundic parietal cells in mouse. **Dig. Dis. Sci.** 55(12):3339-3348, 2010.doi:10.1007/s10620-010-1167-8.
150. Hirata, K., **Suzuki, H.\***, Nishizawa, T., Tsugawa, H., Muraoka, H., Saito, Y., Matsuzaki, J., Hibi, T. Contribution of efflux pumps to clarithromycin resistance in *Helicobacter pylori*. **J. Gastroenterol. Hepatol.** 25(s1):S75-79, 2010.doi:10.1111/j.1440-1746.2009.06220.x.
151. Matsuzaki, J., **Suzuki, H.\***, Tsugawa, H., Nishizawa, T., Hibi, T. Homology model of the DNA gyrase enzyme of *Helicobacter pylori*, a target of quinolone-based eradication therapy. **J. Gastroenterol. Hepatol.** 25(s1):S7-10, 2010.doi:10.1111/j.1440-1746.2010.06245.x.
152. Suzuki, S., **Suzuki, H.\***, Horiguchi, K., Tsugawa, H., Matsuzaki, J., Takagi, T., Shimojima, N., Hibi, T. Delayed gastric emptying and disruption of the interstitial cells of Cajal network after gastric ischemia and reperfusion. **Neurogastroenterol. Motil.** 22(5):585-593, e126, 2010.doi:10.1111/j.1365-2982.2009.01444.x.
153. Matsuzaki, J., **Suzuki, H.\***, Asakura, K., Saito, Y., Hirata, K., Takebayashi, T., Hibi, T. Gallstones increase the prevalence of Barrett's esophagus. **J. Gastroenterol.** 45(2):171-8, 2010.doi:10.1007/s00535-009-0153-4.
154. Imaeda, H., Hosoe, N., Nakamizo, H., Kashiwagi, K., **Suzuki, H.**, Saito, Y., Suganuma, K., Ida, Y., Matsuzaki, J., Iwasaki, E., Iwao, Y., Ogata, H., Hibi, T. Clinical results of observation of the upper gastrointestinal tract by transgastronomic endoscopy using an ultrathin endoscope. **J. Gastroenterol. Hepatol.** 25(12):1850-1854, 2010.doi:10.1111/j.1440-1746.2010.06399.x.
155. Yaguchi, T., Imaeda, H., Kizaki, M., Hosoe, N., **Suzuki, H.**, Ogata, H., Iwao, Y., Kameyama, K., Hibi, T. Partial regression of duodenal lesions of intestinal follicular lymphoma after antibiotic treatment. **Dig. Endosc.** 22:316-318, 2010.doi:10.1111/j.1443-1661.2010.01011.x.
156. Imaeda, H., Hosoe, N., Kashiwagi, K., Ida, Y., Saito, Y., **Suzuki, H.**, Aiura, K., Ogata, H., Kumai, K., Hibi, T. Autofluorescence videoendoscopy system using the SAFE-3000 for assessing superficial gastric neoplasia. **J. Gastroenterol. Hepatol.** 25(4):706-711, 2010.doi:10.1111/j.1440-1746.2009.06202.x.
157. Suzuki, M., **Suzuki, H.**, Minegishi, Y., Ito, K., Nishizawa, T., Hibi, T. *H. pylori* -eradication therapy increases RUNX3 expression in the glandular epithelial cells in enlarged-fold gastritis. **J. Clin. Biochem. Nutr.** 46(3):259-264, 2010.doi:10.3164/jcfn.09-127.
158. Makino, Y., **Suzuki, H.\***, Nishizawa, T., Kameyama, K., Hisamatsu, T., Imaeda, H., Mukai, M., Hibi, T. Ileal mucosa-associated lymphoid tissue (MALT) lymphoma with a large-cell component that regressed spontaneously. **Gut and Liver** 4(1):117-121, 2009.doi:10.5009/gnl.2010.4.1.17.
159. Saito, Y., **Suzuki, H.\***, Tsugawa, H., Nakagawa, I., Matsuzaki, J., Kanai, Y., Hibi, T. Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced *microRNA-512-5p* with downregulation of *Mcl-1* in human gastric cancer cells. **Oncogene** 28(30):2738-44, 2009.doi:10.1038/onc.2009.140.
160. Nishizawa, T., **Suzuki, H.\***, Nakagawa, I., Minegishi, Y., Masaoka, T., Iwasaki, E., Hibi, T. Rebamipide promoted restoration of gastric mucosal sonic hedgehog expression after early *H. pylori* eradication. **Digestion** 79(4):259-262, 2009.doi:10.1159/000213241.
161. **Suzuki, H.\***, Nishizawa, T., Muraoka, H., Hibi, T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of *H. pylori* with *gyrA* mutation. **Antimicrob. Agent Chemother.** 53(4):1720-1721, 2009.doi:10.1128/AAC.00049-09.
162. Nishizawa, T., **Suzuki, H.\***, Nakagawa, I., Minegishi, Y., Masaoka, T., Iwasaki, E., Hibi, T. Early *Helicobacter pylori* eradication restores sonic hedgehog expression in the gastric mucosa of Mongolian gerbils. **Digestion** 79(2):99-108, 2009.doi:10.1159/000209219.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



163. Suzuki, S., **Suzuki, H.\***, Nishizawa, T., Kaneko, F., Ootani, S., Muraoka, H., Saito, Y., Kobayashi, I., Hibi, T. Past rifampicin dosing determines rifabutin resistance of *H. pylori*. **Digestion** 79(1):1-4, 2009.doi:10.1159/000191204.
164. Naito, Y., Kimura, T., Aramaki, M., Izumi, K., Okada, Y., **Suzuki, H.**, Takahashi, T., Kosaki, K. Caudal regression and tracheoesophagea; malformation induced by adriamycin: a novel chick model of VATER association. **Pediatr. Res.** 65(6):607-612, 2009.doi:10.1203/PDR.06013e31819e7317.
165. Imaeda, H., Hosoe, N., Ida, Y., Kashiwagi, K., Morohoshi, Y., Suganuma, K., Nagakubo, S., Komatsu, K., **Suzuki, H.**, Saito, Y., Aiura, K., Ogata, H., Iwao, Y., Kumai, K., Kitagawa, Y., Hibi, T. Novel technique of endoscopic submucosal dissection using an external grasping forceps for superficial gastric neoplasia. **Dig. Endosc.** 21(2):122-127, 2009.doi:10.1111/j.1443-1661.2009.00842.x.
166. Hosoe, N., Imaeda, H., Kashiwagi, K., Naganuma, M., Inoue, N., **Suzuki, H.**, Suganuma, K., Ida, Y., Nakamizo, H., Aiura, K., Ogata, H., Iwao, Y., Kumai, K., Hibi, T. : Clinical results of endoscopic hemostasis using a short transparent hood and short hemoclips for non-variceal upper gastrointestinal bleeding. **Dig. Endosc.** 21(2):93-96, 2009. doi:10.1111/j.1443-1661.2009.00843.x.
167. Iwasaki, E., **Suzuki, H.\***, Sugino, Y., Iida, T., Nishizawa, T., Masaoka, T., Hosoda, H., Kangawa, K., Hibi, T. Decreased levels of adiponectin in obese patients with gastroesophageal reflux evaluated by videoesophagography: possible relationship between gastroesophageal reflux and metabolic syndrome. **J. Gastroenterol. Hepatol.** 23(Suppl.2):S216-S221, 2008.doi:10.1111/j.1440-1746.2008.05441.x.
168. Nishizawa, T., **Suzuki, H.\***, Nakagawa, I., Iwasaki, E., Masaoka, T., Hibi, T. Gatifloxacin-based triple therapy as third-line regimen for *Helicobacter pylori* eradication. **J. Gastroenterol. Hepatol.** 23(Suppl.2):S167-S170, 2008. doi:10.1111/j.1440-1746.2008.05407.x.
169. Tsugawa, H., **Suzuki, H.\***, Nakagawa, I., Nishizawa, T., Saito, Y., Suematsu, M., Hibi, T. Alpha-ketoglutarate oxidoreductase, an essential salvage enzyme of energy metabolism, in coccoid form of *Helicobacter pylori*. **Biochem. Biophys. Res. Com.** 376(1):46-51, 2008.doi:10.1016/j.bbrc.2008.08.078.
170. Ohara, T., Kanoh, Y., Taguma, Y., Hashimoto, H., **Suzuki, H.**, Sakai, Y., Kondo, F., Kameyama, J., Tani, N., Yoshino, K., Kitajima, M. High incidence of Dieulafoy's lesions in upper gastrointestinal bleeding associated with polyarteritis – clinical examination of patients of polyarteritis nodosa with rapidly progressive glomerulonephritis. **HepatoGastroenterol.** 55(84):821-825, 2008.
171. Asahi, A., Nishimoto, T., Okazaki, Y., **Suzuki, H.**, Masaoka, T., Kawakami, Y., Ikeda, Y., Kuwana, M. *Helicobacter pylori* eradication shifts monocytes' Fcγ receptor balance toward inhibitory FcγRIIB in immune thrombocytopenic purpura. **J. Clin. Invest.** 118(8):2939-49, 2008.doi:10.1172/JCI34496.
172. Suzuki, M., Tanaka, S., Suzuki, K., Kitahara, T., Masaoka, T., **Suzuki, H.**, Hibi, T. Persistent oxidative stress in the corpus mucosa is evoked by long-term treatment of *H. pylori* -infected patients with proton pump inhibitors. **HepatoGastroenterol.** 55(81):138-141, 2008.
173. Nishizawa, T., **Suzuki, H.\***, Masaoka, T., Iwasaki, E., Hibi, T. A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of *Helicobacter pylori*. **Digestion** 76(3-4):215-220, 2007.doi:10.1159/000112649.
174. Nishizawa, T., **Suzuki, H.\***, Masaoka, T., Hibi, T. Gastrointestinal: Enhanced gastric mucosal blood flow in aspirin intoxication. **J. Gastroenterol. Hepatol.** 22(11):2037, 2007.doi:10.1111/j.1440-1746.2007.05201.x.
175. Arakawa, M., **Suzuki, H.\***, Minegishi, Y., Fukushima, Y., Masaoka, T., Ishikawa, T., Hosoda, H., Kangawa, K., Hibi, T. Enhanced ghrelin expression and subsequent acid secretion in mice with genetic H<sub>2</sub>-receptor knockout. **J. Gastroenterol.** 42(9):711-8, 2007.doi:10.1007/s00535-007-2084-2.
176. Minegishi, Y., **Suzuki, H.\***, Arakawa, M., Fukushima, Y., Masaoka, T., Ishikawa, T., Wright, N.A., Hibi, T. Reduced Shh expression in TFF2-overexpressing lesions of the gastric fundus under hypochlorhydric conditions. **J. Pathol.** 213(2):161-169, 2007.doi:10.1002/path.2221.
177. Masaoka, T., **Suzuki, H.\***, Hori, S., Aikawa, N., Hibi, T. Blatchford score is useful scoring system to detect the patients who do not need the endoscopic intervention in cases of upper-gastrointestinal hemorrhage in Japan. **J. Gastroenterol. Hepatol.** 22(9):1404-1408, 2007.doi:10.1111/j.1440-1746.2006.04762.x.
178. Nishizawa, T., **Suzuki, H.\***, Masaoka, T., Iwasaki, E., Hibi, T. Reduced conscious blood flow in the stomach during non-steroidal anti-inflammatory drugs administration assessed by flash echo imaging. **Scand. J. Gastroenterol.** 42(9):1040-1044, 2007.doi:10.1080/00365520701216968.
179. **Suzuki, H.**, Kim, O. Water extract of *Helicobacter pylori* can induce caspase-3-dependent apoptosis. **Lab. Anim. Res.** 23(3):285-288, 2007.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



180. Nishizawa, T., **Suzuki, H.\***, Masaoka, T., Minegishi, Y., Iwasaki, E., Hibi, T. *Helicobacter pylori* eradication restored sonic hedgehog expression in the human stomach. **HepatoGastroenterol.** 54(75):697-700, 2007.
181. Nishizawa, T., **Suzuki, H.\***, Umezawa, A., Muraoka, H., Iwasaki, E., Masaoka, T., Kobayashi, I., Hibi, T. Rapid detection of point mutations conferring resistance to fluoroquinolone in the *gyrA* of *Helicobacter pylori* by allele-specific polymerase chain reaction. **J. Clin. Microbiol.** 45(2):303-305, 2007.doi:10.1128/JCM.01997-06.
182. Terano, A., Arakawa, T., Sugiyama, T., **Suzuki, H.**, Joh, T., Yoshikawa, T., Higuchi, K., Haruma, K., Murakami, K., Kobayashi, K; for the Rebamipide Clinical Study Group. Rebamipide, a gastroprotective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for *Helicobacter pylori* in a Japanese population: a randomized, double-blind, placebo-controlled trial. **J. Gastroenterol.** 42(8):690-3, 2007.doi:10.1007/s00535-007-2076-2.
183. Izumi, K., Aramaki, M., Kimura, T., Naito, Y., Uda, T., Uchikawa, M., Kondoh, H., **Suzuki, H.**, Okada, Y., Takahashi, T., Golden, J.A., Kosaki, K. Identification of a proencephalon-specific enhancer of *SALL1*: Comparative genomic approach using the chick embryo. **Pediatr. Res.** 61(6):660-665, 2007.doi:10.1203/pdr.0b013e318053423a.
184. Dierikx, C.M., Martodihardjo, J., Kuipers, E.J., Hensgens, C.M., Kusters, J.G., **Suzuki, H.**, de Groot, N., van Vliet, A.H. Serum- and animal tissue-free medium (SATFM) for transport and growth of *Helicobacter pylori*. **FEMS Immunol. Med. Microbiol.** 50(2):239-243, 2007.doi:10.1111/j.1574-695x.2007.00211.x.
185. **Suzuki, H.**, Kim, O. *Helicobacter pylori* infection induces inflammatory cytokine production in alternative model to animal tests for assessing the pathogenesis. **Lab. Anim. Res.** 22(4):349-353, 2006.
186. **Suzuki, H.\***, Masaoka, T., Nomoto, Y., Hosoda, H., Mori, M., Nishizawa, T., Minegishi, Y., Kangawa, K., Hibi, T. Increased levels of plasma ghrelin in peptic ulcer disease. **Aliment. Pharm. Ther.** 24(Suppl. 4):120-126, 2006.doi:10.1111/j.1365-2036.2006.00034.x.
187. Nishizawa, T., **Suzuki, H.\***, Nomoto, Y., Masaoka, T., Hosoda, H., Mori, M., Ohara, T., Morishita, T., Kangawa, K., Hibi, T. Enhanced plasma ghrelin levels in patients with functional dyspepsia. **Aliment. Pharm. Ther.** 24(Suppl. 4):104-110, 2006.doi:10.1111/j.1746-6342.2006.00032.x.
188. Mori, M., **Suzuki, H.\***, Masaoka, T., Imaeda, H., Nomoto, Y., Hosoda, H., Nishizawa, T., Kangawa, K., Hibi, T. Intravenous ghrelin administration enhances gastric acid secretion - evaluation using wireless pH capsule - **Aliment. Pharm. Ther.** 24(Suppl. 4):96-103, 2006.doi:10.1111/j.1746-6342.2006.00031.x.
189. Masaoka, T., **Suzuki, H.\***, Kurabayashi, K., Nomoto, Y., Nishizawa, T., Mori, M., Hibi, T. Could frameshift mutations in the *frxA* and *rdxA* genes of *Helicobacter pylori* be a marker for metronidazole resistance? **Aliment. Pharm. Ther.** 24(Suppl. 4):81-87, 2006.doi:10.1111/j.1365-2036.2006.00029.x.
190. Nishizawa, T., **Suzuki, H.\***, Kurabayashi, K., Masaoka, T., Muraoka, H., Mori, M., Iwasaki, E., Kobayashi, I., Hibi, T. Gatifloxacin resistance and mutations in *gyrA* after unsuccessful *Helicobacter pylori* eradication in Japan. **Antimicrob. Agent Chemother.** 50(4):1538-1540, 2006.doi:10.1128/AAC.50.4.1538-1540.2006.
191. Nishizawa, T., **Suzuki, H.\***, Masaoka, T., Nomoto, Y., Minegishi, Y., Hosoda, H., Mori, M., Ohara, T., Morishita, T., Kangawa, K., Hibi, T. Emotional stress enhanced ghrelin secretion from the stomach. **J. Clin. Biochem. Nutri.** 38(1):33-37, 2006.doi:10.3164/jcbs.38.33.
192. Ohara, T., Kasanuki, J., Ohara, H., Kanoh, Y., **Suzuki, H.**, Hashimoto, H., Chiba, T., Morishita, T., Hibi, T. Analysis of the differences in structural chromosomal aberrations of the gastric mucosa between *H. pylori* positive and negative gastric cancer patients: Involvement of *H. pylori* in the onset of gastric cancer and examination of the mechanism in gastric carcinogenesis following *H. pylori* eradication. **Oncol. Rep.** 16(6):1333-1342, 2006.doi:10.3892/or.16.6.1333.
193. Osaki, T., Hanawa, T., Manzoku, T., Fukuda, M., Kawakami, H., **Suzuki, H.**, Yamaguchi, H., Yen, X., Taguchi, H., Kurata, S., Kamiya, S. Mutation of *luxS* affects motility and infectivity of *Helicobacter pylori* in gastric mucosa of Mongolian gerbil model. **J. Med. Microbiol.** 55(11):1477-1485, 2006.
194. Asahi, A., Kuwana, M., **Suzuki, H.**, Hibi, T., Kawakami, Y., Ikeda, Y. Effects of a *Helicobacter pylori* eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. **Haematologica** 91(10):1436-1437, 2006.
195. Suzuki, M., Tanaka, S., Komatsu, T., Nakane, T., Sasaki, N., Maruyama, K., **Suzuki, H.**, Ishii, H., Suematsu, M., Hibi, T. Evaluation of alcohol metabolism in humans using the non-invasive [<sup>13</sup>C]-ethanol breath test - influence of gender, *Helicobacter pylori* infection and polymorphism of alcohol-oxidizing enzymes. **Aliment. Pharm. Ther.** 24(Suppl. 4):177-181, 2006.doi:10.1111/j.1365-2036.2006.00042.x.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



196. Ohara, T., Kasanuki, J., Morishita, T., Yamamoto, N., Shibahara, T., **Suzuki, H.**, Masaoka, T., Nishizawa, T., Hibi, T. Evaluation of the role of *Helicobacter pylori* as a promoter of gastric cancer from the viewpoint of structural chromosomal aberration. **Aliment. Pharm. Ther.** 24(Suppl. 4):111-119, 2006.doi:10.1111/j.1365-2036.2006.00033.x.
197. Ohara, T., Morishita, T., **Suzuki, H.**, Hibi, T. Heterozygous Thr 135 Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas. **Int. J. Mol. Med.** 18(1):59-63, 2006.doi:10.3892/ijmm.18.1.59.
198. Matsuhisa, T., Kawai, T., Masaoka, T., **Suzuki, H.**, Ito, M., Kawamura, Y., Tokunaga, K., Suzuki, M., Mine, T., Takahashi, S., Sakaki, N. Efficacy of metronidazole as second-line drug for the treatment of *Helicobacter pylori* infection in the Japanese population: a multicenter study in the Tokyo Metropolitan area. **Helicobacter** 11(3):152-8, 2006.doi:10.1111/j.1523-5378.2006.00394.x.
199. Imaeda, H., Iwao, Y., Ogata, H., Ichikawa, H., Mori, M., Hosoe, N., Masaoka, T., Nakashita, M., **Suzuki, H.**, Inoue, N., Aiura, K., Nagata, H., Kumai, K., Hibi, T. A new technique for endoscopic submucosal dissection for early gastric cancer using an external grasping forceps. **Endoscopy** 38(10):1007-1010, 2006.doi:10.1055/s-2006-925264.
200. Bolkent, S., Yanardag, R., Bolkent, S., Mutlu, O., Yildirim, S., Kangawa, K., Minegishi, Y., **Suzuki, H.** The effect of zinc supplementation on ghrelin immunoreactive cells and lipid parameters in gastrointestinal tissue of streptozotocin-induced female rats. **Mol. Cell. Biochem.** 286(1-2):77-85, 2006.doi:10.1007/s11010-005-9095-1.
201. Nagata, H., Akiba, Y., **Suzuki, H.**, Okano, H., Hibi, T. Expression of Musashi-1 in the rat stomach and changes during mucosal injury and restitution. **FEBS Lett.** 580(1):27-33, 2006.doi:10.1016/j.febslet.2005.11.041.
202. Ohara, T., Morishita, T., Hashimoto, H., Akimoto, M., Nakajima, N., **Suzuki, H.**, Hibi, T. Analysis of Toll-like receptor 2, 4, 6 and 9 genome DNA mutations in patients with tractable and intractable gastric mucosal diseases. **Int. J. Mol. Med.** 17(1):53-8, 2006.doi:10.3892/ijmm.17.1.53.
203. **Suzuki, H.\***, Masaoka, T., Sakai, G., Ishii, H., Hibi, T. Improvement of gastrointestinal quality of life (QOL) scores in cases of *Helicobacter pylori* -positive functional dyspepsia after successful eradication therapy. **J. Gastroenterol. Hepatol.** 20(11):1652-1660, 2005.doi:10.1111/j.1440-1746.2005.04039.x.
204. Abiko, Y., **Suzuki, H.\***, Masaoka, T., Nomura, S., Kurabayashi, K., Hosoda, H., Kangawa, K., Hibi, T. Enhanced plasma ghrelin levels in *H. pylori* -colonized, interleukin-1 receptor type 1-homozygous knockout (IL-1R1<sup>-/-</sup>) mice. **World J. Gastroenterol.** 11(27):4148-4153, 2005.doi:10.3748/wjg.v11.i27.4148.
205. Fukuhara, S., **Suzuki, H.\***, Masaoka, T., Arakawa, M., Hosoda, H., Minegishi, Y., Kangawa, K., Ishii, H., Kitajima, M., Hibi, T. Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers. **Am. J. Physiol., Gastrointest. Liver Physiol.** 289(1):G138-G145, 2005.doi:10.1152/ajpgi.00298.2004.
206. **Suzuki, H.\***, Minegishi, Y., Nomoto, Y., Ota, T., Masaoka, T., van den Brink, G.R., Hibi, T. Downregulation of a morphogen (sonic hedgehog) gradient in the gastric epithelium of *Helicobacter pylori*-infected Mongolian gerbils. **J. Pathol.** 206(2):186-197, 2005.doi:10.1002/path.1763.
207. Nomura, S., **Suzuki, H.\***, Masaoka, T., Kurabayashi, K., Ishii, H., Kitajima, M., Nomoto, K., Hibi, T. Effect of dietary anti-urease immunoglobulin Y on *Helicobacter pylori* infection in Mongolian gerbils. **Helicobacter** 10(1):43-52, 2005.doi:10.1111/j.1523-5378.2005.00290.x.
208. Masaoka, T., **Suzuki, H.\***, Imaeda, H., Hosoda, H., Ohara, T., Morishita, T., Ishii, H., Kangawa, K., Hibi, T. Long-term strict monitoring of plasma ghrelin and other serological markers of gastric diseases after *Helicobacter pylori* eradication. **HepatoGastroenterol.** 52(61):1-4, 2005.
209. Ohara, T., Morishita, T., **Suzuki, H.**, Masaoka, T., Nishizawa, T., Hibi, T. Investigation of the possibility of human-beta defensin 2 (hBD2) as a molecular marker of gastric mucosal inflammation. **HepatoGastroenterol.** 52(65):1320-1324, 2005.
210. Matsumoto, M., Yokoyama, H., **Suzuki, H.**, Shiraishi-Yokoyama, H., Hibi, T. Retinoic acid formation from retinol in the human gastric mucosa: a role of Class IV alcohol dehydrogenase and its relevance to morphological changes. **Am. J. Physiol., Gastrointest. Liver Physiol.** 289(3):G429-G433, 2005.doi:10.1152/ajpgi.00502.2004.
211. Kato, S., Tsuzuki, Y., Hokari, R., Okada, Y., Miyazaki, J., Matsuzaki, K., Iwai, A., Kawaguchi, A., Nagao, S., Itoh, K., **Suzuki, H.**, Nabeshima, T., Miura, S. Role of nociceptin/orphanin FQ (Noc/oFQ) in murine experimental colitis. **J. Neuroimmunol.** 161(1-2):21-8, 2005.doi:10.1016/j.jneuroim.2004.12.006.
212. Nishimura, T., Masaoka, T., **Suzuki, H.\***, Aiura, K., Nagata, H., Ishii, H. Autoimmune pancreatitis with pseudocysts. **J. Gastroenterol.** 39(10):1005-1010, 2004.doi:10.1007/s00535-004-1436-4.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



213. **Suzuki, H.\***, Masaoka, T., Hosoda, H., Nomura, S., Ohara, T., Kangawa, K., Ishii, H., Hibi, T. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio - a possible novel and non-invasive marker for gastric atrophy. **HepatoGastroenterol.** 51(59):1249-1254, 2004.
214. **Suzuki, H.\***, Nomura, S., Masaoka, T., Goshima, H., Kamata, N., Kodama, Y., Ishii, H., Kitajima, M., Nomoto, K., Hibi, T. Effect of dietary anti-*Helicobacter pylori* -urease immunoglobulin Y on *Helicobacter pylori* infection. **Aliment. Pharm. Ther.** 20(Suppl. 1):185-192, 2004.doi:10.1111/j.1365-2036.2004.02027.
215. Masaoka, T., **Suzuki, H.\***, Kurabayashi, K., Kamiya, A.G., Ishii, H. Second-line treatment of *Helicobacter pylori* infection after dilution agar methods and PCR-RFLP analysis. **Aliment. Pharm. Ther.** 20(Suppl. 1):68-73, 2004.doi:10.1111/j.1365-2036.2004.01994.x.
216. Kaneko, F., **Suzuki, H.\***, Hasagawa, N., Kurabayashi, K., Saito, H., Otani, S., Nakamizo, H., Kawata, K., Miyairi, M., Ishii, K., Ishii, H. High prevalence of *Helicobacter pylori* resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. **Aliment. Pharm. Ther.** 20(Suppl. 1):62-67, 2004.doi:10.1111/j.1365-2036.2004.01993.x.
217. **Suzuki, H.\***, Masaoka, T., Minegishi, Y., Motosugi, Y., Miura, S., Ishii, H. Lansoprazole promotes gastric mucosal cell proliferation and migration by activating p44/p42 mitogen-activated protein kinase. **Wound Repair. Regen.** 12 (1):93-99, 2004.doi:10.1111/j.1067-1927.2004.012116.x.
218. **Suzuki, H.\***, Masaoka, T., Hosoda, H., Ota, T., Minegishi, Y., Nomura, S., Kangawa, K., Ishii, H. *Helicobacter pylori* infection modifies gastric and plasma ghrelin dynamics in Mongolian gerbils. **Gut** 53(2):187-194, 2004.doi:10.1136/gut.2003.021568.
219. Ohara, T., Morishita, T., **Suzuki, H.**, Masaoka, T., Ishii, H., Hibi, T. Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. **Anticancer Res.** 24(6):3723-3730, 2004.
220. Nagata, H., Arai, T., Soejima, Y., **Suzuki, H.**, Ishii, H., Hibi, T. Limited capability of regional lymph nodes to eradicate metastatic cancer cells. **Cancer Res.** 64(22):8239-48, 2004.doi:10.1158/0008-5472.CAN-04-1182.
221. Ohara, T., Morishita, T., **Suzuki, H.**, Nagata, H., Hibi, T. Pathophysiological role of human  $\beta$ -defensins 2 in gastric mucosa. **Int. J. Mol. Med.** 14(6):1023-7, 2004.doi:10.3892/ijmm.14.6.1023.
222. Suzuki, M., **Suzuki, H.**, Masaoka, T., Tanaka, S., Suzuki, K., Ishii, H. *Helicobacter pylori* -eradication treatment modulates epithelial cell proliferation and tissue content of hepatocyte growth factor in the gastric mucosa. **Aliment. Pharm. Ther.** 20(Suppl. 1):158-164, 2004.doi:10.1111/j.1365-2036.2004.01971.x.
223. Suzuki, M., Maruyama, K., **Suzuki, H.**, Ishii, H. <sup>13</sup>C-ethanol breath test reveals impaired alcohol metabolism in patients with *Helicobacter pylori* -infection. **Aliment. Pharm. Ther.** 20(1):109-15, 2004.doi:10.1111/j.1365-2036.2004.02020.x.
224. Ohara, T., **Suzuki, H.**, Kanoh, Y., Moriya, R., Okayasu, I., Morishita, T., Ishii, H. Regular hemodialysis reverses gastric mucosal atrophy of patients with chronic renal failure. **HepatoGastroenterol.** 51(57):679-683, 2004.
225. Miwa, H., Sakaki, N., Sugano, K., Sekine, H., Higuchi, K., Uemura, N., Kato, M., Murakami, K., Kato, C., Shiotani, A., Ohkusa, T., Takagi, A., Aoyama, N., Haruma, K., Okazaki, K., Kusugami, K., Suzuki, M., Joh, T., Azuma, T., Yanaka, A., **Suzuki, H.**, Hashimoto, H., Kawai, T., Sugiyama, T. Recurrent peptic ulcers in patients following successful *Helicobacter pylori* eradication. : a multicenter study of 4940 patients. **Helicobacter** 9(1):9-16, 2004.doi:10.1111/j.1083-4389.2004.00194.x.
226. Kaneko, F., Saito, H., Saito, Y., Wakabayashi, K., Nakamoto, N., Tada, S., **Suzuki, H.**, Tsunematsu, S., Kumagai, N., Ishii, H. Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate. **Int. J. Oncol.** 24(4):837-45, 2004.doi:10.3892/ijo.24.4.837.
227. Ohara, T., Morishita, T., **Suzuki, H.**, Masaoka, T., Ishii, H. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with *H. pylori* -negative recurrent peptic ulcer after eradication therapy for *H. pylori* : pathophysiological characteristics of *H. pylori* -negative recurrent ulcer scars and beyond acid suppression by PPI. **HepatoGastroenterol.** 51(56):338-342, 2004.
228. **Suzuki, H.\***, Miyazawa, M., Nagahashi, S., Sato, M., Bessho, M., Nagata, H., Miura, S., Ishii, H. Rabepazole treatment attenuated *H. pylori* -associated gastric mucosal lesion formation in Mongolian gerbils. **J. Gastroenterol. Hepatol.** 18(7):787-795, 2003.doi:10.1046/j.1440-1746.2003.03038.x.
229. Miyazawa, M., **Suzuki, H.\***, Masaoka, T., Kai, A., Suematsu, M., Nagata, H., Miura, S., Ishii, H. Suppressed apoptosis in the inflamed gastric mucosa of *H. pylori* -colonized iNOS knockout mice. **Free Radic. Biol. Med.** 34(12):1621-1630, 2003.doi:10.1016/s0891-5849(03)00218-1.





# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



230. Masaoka, T., **Suzuki, H.\***, Hosoda, H., Ota, T., Minegishi, Y., Kangawa, K., Nagata, H., Ishii, H. Enhanced plasma ghrelin levels in rats with streptozotocin-induced diabetes. **FEBS Lett.** 541(1-3):64-68, 2003.doi:10.1016/s0014-5793103200306-5.
231. Ohara, T., Morishita, T., **Suzuki, H.**, Masaoka, T., Ishii, H. Perforin and granzyme B of cytotoxic T lymphocyte mediate apoptosis irrespective of *Helicobacter pylori* infection : possible act as a trigger of peptic ulcer formation. **HepatoGastroenterol.** 50(54):1774-9, 2003.
232. Suzuki, M., **Suzuki, H.**, Kitahora, T., Nagahashi, S., Masaoka, M., Tanaka, S., Suzuki, K., Ishii, H. *Helicobacter pylori* - eradication therapy inhibits neutrophil-derived oxidants in the ulcerous mucosa in the human stomach: Relationship between ulcer stage and mucosal oxidant level. **Dig. Endosc.** 15(4):270-275, 2003.
233. Uehara, K., Miura, S., Takeuchi, T., Taki, T., Nakashita, M., Adachi, M., Inamura, T., Ogawa, T., Akiba, Y., **Suzuki, H.**, Nagata, H., Ishii, H. Significant role of ceramide pathway in experimental gastric ulcer formation in rats. **J. Pharmacol. Exp. Ther.** 305(1):232-9, 2003.
234. Nagahashi, S., **Suzuki, H.\***, Miyazawa, M., Nagata, H., Suzuki, M., Miura, S., Ishii, H. Ammonia aggravates stress-induced gastric mucosal oxidative injury through the cancellation of cytoprotective heat shock protein 70. **Free Radic. Biol. Med.** 33(8):1073-1081, 2002.doi:10.1124/jpet.102.045195.
235. **Suzuki, H.\***, Miyazawa, M., Kai, A., Suzuki, M., Suematsu, M., Miura, S., Ishii, H. No difference in the level of gastric mucosal cell apoptosis and proliferation in *Helicobacter pylori* -colonized p53 heterozygous knockout mice. **Aliment. Pharm. Ther.** 16(Suppl.2):158-166, 2002.doi:10.1046/j.1365-2036.16.s2.18.x.
236. **Suzuki, H.\***, Miyazawa, M., Nagahashi, S., Mori, M., Seto, K., Kai, A., Suzuki, M., Miura, S., Ishii, H. Attenuated apoptosis in *H. pylori* -colonized gastric mucosa of Mongolian gerbils – in comparison with mice-. **Dig. Dis. Sci.** 47(1):90-99, 2002.doi:10.1023/A:1013219621422.
237. Hatanaka, K., Hokari, R., Matsuzaki, K., Kato, S., Kawaguchi, A., Nagao, S., **Suzuki, H.**, Miyazaki, K., Sekizuka, E., Nagata, H., Ishii, H., Miura, S. Increased expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and lymphocyte recruitment in murine gastritis induced by *Helicobacter pylori*. **Clin. Exp. Immunol.** 130(2):183-9, 2002.doi:10.1046/j.1365-2249.2002.01984.x.
238. Kishikawa, H., Miura, S., Yoshida, H., Hirokawa, M., Nakamizo, H., Higuchi, H., Adachi, M., Nakatsumi, R.C., **Suzuki, H.**, Saito, H., Ishii, H. Transmural pressure induces IL-6 secretion by intestinal epithelial cells. **Clin. Exp. Immunol.** 129(1):86-91, 2002.
239. Zeki, S., Miura, S., **Suzuki, H.**, Watanabe, N., Adachi, M., Yokoyama, H., Horie, Y., Saito, H., Kato, S., Ishii, H. Xanthine oxidase-derived oxygen radicals play significant roles in the development of chronic pancreatitis in WBN/Kob rats. **J. Gastroenterol. Hepatol.** 17(5):606-616, 2002.doi:10.1046/j.1440-1746.2002.02733.x.
240. Suzuki, M., **Suzuki, H.**, Kitahora, T., Miyazawa, M., Nagahashi, S., Suzuki, K., Ishii, H. Proton pump inhibitor modifies inflammatory reaction in human gastric mucosa infected by *Helicobacter pylori*. **Aliment. Pharm. Ther.** 16(Suppl.2):229-234, 2002.
241. Suzuki, M., **Suzuki, H.**, Kitahora, T., Miyazawa, M., Nagahashi, S., Suzuki, K., Ishii, H. Treatment with a proton pump inhibitor promotes corpus gastritis in patients with *Helicobacter pylori*-infected antrum-predominant gastritis. **Aliment. Pharm. Ther.** 16(1):159-165, 2002.doi:10.1046/j.1365-2036.16.s2.19.x.
242. **Suzuki, H.\***, Mori, M., Seto, K., Miyazawa, M., Kai, A., Suematsu, M., Yoneta, T., Miura, S., Ishii, H. Polaprezinc attenuates the *H. pylori*-induced gastric mucosal leukocyte activation in Mongolian gerbils. – a study using intravital videomicroscopy – **Aliment. Pharmacol. Ther.** 15(5):715-725, 2001.doi:10.1046/j.1365-2036.2001.00960.x.
243. Yoshida, H., Miura, S., Kishikawa, H., Hirokawa, M., Nakamizo, H., Nakatsumi, R.C., **Suzuki, H.**, Saito, H., Ishii, H. Fatty acids enhance GRO/CINC-1 and Interleukin-6 production in rat intestinal epithelial cells. **J. Nutr.** 131 (11):2943-2950, 2001.
244. Hirokawa, M., Miura, S., Kishikawa, H., Yoshida, H., Nakamizo, H., Higuchi, H., Nakatsumi, R.C., **Suzuki, H.**, Saito, H., Ishii, H. Loading of mechanical pressure activates mitogen-activated protein kinase and early immediate gene in intestinal epithelial cells. **Dig. Dis. Sci.** 46 (9):1993-2003, 2001.doi:10.1023/A:1010607819842.
245. Matsumoto, M., Yokoyama, H., Shiraishi, H., **Suzuki, H.**, Kato, S., Miura, S., Ishii, H. Alcohol dehydrogenase activities in the human gastric mucosa: effects of *Helicobacter pylori* infection, sex, age, and the part of the stomach. **Alcoholism Clin. Exp. Res.** 25(6 Suppl.):29S-34S, 2001.doi:10.1111/j.1530-0277.2001.tb02414.x.
246. Han, J-Y., Miura, S., Akiba, Y., Higuchi, H., Kato, S., **Suzuki, H.**, Yokoyama, H., Ishii, H. Chronic ethanol consumption exacerbates microcirculatory damage in rat mesentery following reperfusion. **Am. J. Physiol., Gastrointest Liver Physiol.** 280(5):G939-48, 2001.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



247. Fujimori, H., Miura, S., Koseki, S., Hokari, R., Tsuzuki, Y., Komoto, S., Hara, Y., **Suzuki, H.**, Serizawa, H., Ishii, H. Intravital demonstration of modulation of T lymphocyte migration by CINC/gro in rat Peyer's patches. **Digestion** 63(Suppl. 1):97-102, 2001.doi:10.1159/000051919.
248. **Suzuki, H.\***, Mori, M., Seto, K., Shibata, F., Nagahashi, S., Kawaguchi, C., Suzuki, M., Matsui, H., Watanabe, K., Miura, S., Ishii, H. Rat CXC chemokine GRO/CINC-1 paradoxically stimulates the growth of gastric epithelial cells. **Aliment. Pharmacol. Ther.** 14(Suppl. 1):94-100, 2000.doi:10.1046/j.1365-2036.2000.014s1094.x.
249. Nagata, H., Hokari, R., **Suzuki, H.**, Miura, S., Sekizuka, E., Ishii, H. *In vivo* identification of parasinus macrophage in the mesenteric lymph node. **Clin Hemorheol Microcirc.** 23(2-4):345-8, 2000.
250. Yokoyama, T., Otani, Y., Kurihara, N., Sakurai, Y., Kameyama, K., **Suzuki, H.**, Igarashi, N., Kimata, M., Wada, N., Kubota, T., Kumai, K., Kitajima, M. Matrix metalloproteinase expression in cultured gastric wall fibroblasts - interactions with *Helicobacter pylori* isolated from patients with ulcers. **Aliment. Pharmacol. Ther.** 14(Suppl. 1):193-198, 2000.doi:10.1046/j.1365-2036.2000.014s1193.x.
251. Kitajima, M., Takahashi, S., Ueda, M., Hoshimoto, S., Koizumi, J., Matsumoto, K., **Suzuki, H.**, Takeda, A., Kutsuki, S., Okita, H., Hata, J. A case of aortoduodenal fistula occurring after surgery and radiation for pancreatic cancer. **Keio J. Med.** 49(1):35-44, 2000.
252. **Suzuki, H.\***, Mori, M., Seto, K., Nagahashi, S., Kawaguchi, C., Morita, H., Suzuki, M., Miura, S., Yoneta, T., Ishii, H. Polaprezinc, a gastroprotective agent: attenuation of monochloramine-evoked gastric DNA fragmentation. **J. Gastroenterol.** 34(Suppl.11):43-46, 1999.
253. **Suzuki, H.\***, Mori, M., Seto, K., Nagahashi, S., Kawaguchi, C., Kai, A., Akiba, Y., Suzuki, M., Suematsu, M., Miura, S., Ishii, H. Ethanol intake preceding *H. pylori* inoculation promotes gastric mucosal inflammation in Mongolian gerbils. **J. Gastroenterol. Hepatol.** 14(11):1062-1069, 1999.doi:10.1046/j.1440-1746.1999.01999.x.
254. **Suzuki, H.**, Mori, M., Kawaguchi, C., Adachi, M., Miura, S., Ishii, H. Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma. **Int. J. Oncol.** 14(6):1087-1090, 1999. doi:10.3892/ijo.14.6.1087.
255. **Suzuki, H.**, DeLano, F.A., Jamshidi, N., Katz, D., Mori, M., Kosaki, K., Gottlieb, R.A., Ishii, H., Schmid-Schönbein, G.W. Enhanced DNA fragmentation in the thymus of spontaneously hypertensive rats. **Am. J. Physiol., Heart & Circ. Physiol.** 276(6 Pt 2):H2135-H2140, 1999.
256. **Suzuki, H.**, Miura, S., Mori, M., Akiba, Y., Nagahashi, S., Zweifach, B.W., Ishii, H., Schmid-Schönbein, G.W. Protective role of adrenal glucocorticoids for gastric mucosa in spontaneously hypertensive rats. **J. Gastroenterol. Hepatol.** 14(4):376-383, 1999.doi:10.1046/j.1440-1746.1999.01861.x.
257. **Suzuki, H.**, Mori, M., Seto, K., Kai, A., Kawaguchi, C., Suzuki, M., Suematsu, M., Yoneta, T., Miura, S., Ishii, H. *H. pylori*-associated gastric pro- and anti-oxidant formation in Mongolian gerbils. **Free Radic. Biol. Med.** 26(5-6):679-684, 1999.doi:10.1016/s0891-5849(98)00248-2.
258. **Suzuki, H.**, Seto, K., Shinoda, Y., Mori, M., Ishimura, Y., Suematsu, M., Ishii, H. Paracrine upregulation of VEGF receptor mRNA in endothelial cells by hypoxia-exposed HepG<sub>2</sub> cells. **Am. J. Physiol., Gastrointest. Liver Physiol.** 276(1 Pt 1):G92-G97, 1999.
259. Sakaguchi, A.A., Miura, S., Takeuchi, T., Hokari, R., Mizumori, M., Yoshida, H., Higuchi, H., Mori, M., Kimura, H., **Suzuki, H.**, Ishii, H. Increased expression of inducible nitric oxide synthase and peroxynitrite in *Helicobacter pylori* gastric ulcer. **Free Radic. Biol. Med.** 27(7-8):781-789, 1999.doi:10.1016/s0891-5849(99)00124-0.
260. Suzuki, M., Mori, M., Fukumura, D., **Suzuki, H.**, Miura, S., Ishii, H. Omeprazole attenuates neutrophil-endothelial cell adhesive interaction induced by extracts of *Helicobacter pylori*. **J. Gastroenterol. Hepatol.** 14(1):27-31, 1999.doi:10.1046/j.1440-1746.1999.01809.x.
261. Mori, M., Suematsu, M., Kyokane, T., Sano, T., **Suzuki, H.**, Yamaguchi, T., Ishimura, Y., Ishii, H. Carbon monoxide mediated alterations in paracellular permeability and vesicular transport in acetaminophen-treated perfused rat liver. **Hepatology** 30(1):160-168, 1999.doi:10.1002/hep.51300110.
262. **Suzuki, H.**, Seto, K., Mori, M., Suzuki, M., Miura, S., Ishii, H. Monochloramine (NH<sub>2</sub>Cl) induced DNA fragmentation in gastric cell line, MKN45. **Am. J. Physiol., Gastrointest. Liver Physiol.** 275(4 Pt 1):G712-G716, 1998.
263. **Suzuki, H.**, Mori, M., Kai, A., Suzuki, M., Suematsu, M., Miura, S., Ishii, H. Effect of rebamipide on *H. pylori*-associated gastric mucosal injury in Mongolian gerbils. **Dig. Dis. Sci.** 43(9 Suppl.):181S-187S, 1998.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



264. **Suzuki, H.**, Mori, M., Sakaguchi, A.A., Suzuki, M., Miura, S., Ishii, H. Enhanced levels of C-X-C chemokine, human GRO $\alpha$ , in *H. pylori*-associated gastric disease. **J. Gastroenterol. Hepatol.** 13(5):516-520, 1998.doi:10.1111/j.1440-1746.1998.tb00679.x.
265. **Suzuki, H.**, DeLano, F.A., Parks, D.A., Jamshidi, N., Granger, D.N., Ishii, H., Suematsu, M., Zweifach, B.W., Schmid-Schönbein, G.W. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. **Proc. Natl. Acad. Sci. USA** 95(8):4754-4759, 1998.
266. **Suzuki, H.**, Suzuki, M., Mori, M., Kitahora, T., Yokoyama, H., Miura, S., Hibi, T., Ishii, H. Augmented levels of gastric mucosal leukocyte activation by infection with *cagA* gene positive-*Helicobacter pylori*. **J. Gastroenterol. Hepatol.** 13(3):294-300, 1998.doi:10.1111/j.1440-1746.1998.01558.x.
267. Suzuki, M., Kitahora, T., Nagahashi, S., **Suzuki, H.**, Mori, M., Hibi, T., Ishii, H. Gastric urease activity is inversely associated with the success of treatment for *Helicobacter pylori*: effect of sofalcone. **J. Clin. Gastroenterol.** 27(Suppl.1):S183-S186, 1998.
268. Akiba, Y., Nakamura, M., Mori, M., **Suzuki, H.**, Oda, M., Kimura, H., Miura, S., Tsuchiya, M., Ishii, H. Inhibition of inducible nitric oxide synthase delays gastric ulcer healing in the rat. **J. Clin. Gastroenterol.** 27(Suppl.1):S64-S73, 1998.
269. Ohki, E., Kato, S., Ohgo, H., Mizukami, T., Fukuda, M., Tamai, H., Okamura, Y., Matsumoto, M., **Suzuki, H.**, Yokoyama, H., Ishii, H. Effect of chronic ethanol feeding on endotoxin-induced hepatic injury: role of adhesion molecules on leukocytes and hepatic sinusoid. **Alcoholism Clin. Exp. Res.** 22(3 Suppl.):129S-132S, 1998.doi:10.1097/0000374-199803001-0011.
270. **Suzuki, H.**, Mori, M., Suzuki, M., Sakurai, K., Miura, S., Ishii, H. Extensive DNA damage induced by monochloramine in gastric cells. **Cancer Lett.** 115(2):243-248, 1997.doi:10.1016/s0304-3835(97)04745-9.
271. Mori, M., **Suzuki, H.\***, Suzuki, M., Kai, A., Miura, S., Ishii, H. Catalase and superoxide dismutase secreted from *Helicobacter pylori*. **Helicobacter** 2(2):100-105, 1997.doi:10.1111/j.1523-5378.1997.tb00067.x.
272. Suzuki, M., Mori, M., Miyayama, A., Iwai, N., Tsunemastu, N., Oonuki, M., **Suzuki, H.**, Hibi, T., Ishii, H. Enhancement of neutrophil infiltration in the corpus after failure of *Helicobacter pylori* eradication. **J. Clin. Gastroenterol.** 25(Suppl.1):S222-S228, 1997.
273. Horie, Y., Kato, S., Ohki, E., Hamamatsu, H., Fukumura, D., Kurose, I., **Suzuki, H.**, Suematsu, M., Miura, S., Ishii, H. Effect of lipopolysaccharides on erythrocyte flow velocity in rat liver. **J. Gastroenterol.** 32(6):783-790, 1997.doi:10.1007/BF02936955.
274. Kosaki, K., **Suzuki, H.**, Schmid-Schönbein, G.W., Nelson, T.R., Jones, K.L. Parametric imaging of the chick embryonic cardiovascular system: A novel functional measure. **Pediatr. Res.** 41(4 Pt 1):451-456, 1997.doi:10.1203/00006450-199704000-00001.
275. **Suzuki, H.**, Miura, S., Imaeda, H., Suzuki, M., Han, J.Y., Mori, M., Fukumura, D., Tsuchiya, M., Ishii, H. Enhanced levels of chemiluminescence and platelet activating factor in urease positive gastric ulcers. **Free Radic. Biol. Med.** 20(3):449-454, 1996.doi:10.1016/0891-5849(96)02048-5.
276. **Suzuki, H.**, Zweifach, B.W., Schmid-Schönbein, G.W. Glucocorticoid modulates vasodilator response of mesenteric arterioles in spontaneously hypertensive rats. **Hypertension** 27(1):114-118, 1996.doi:10.1161/01.HYP.27.1.114.
277. Ohki, E., Kato, S., Horie, Y., Mizukami T., Tamai T., Yokoyama, H., Ito, D., Fukuda, M., **Suzuki, H.**, Kurose, I., Ishii, H. Chronic ethanol consumption enhances endotoxin induced hepatic sinusoidal leukocyte adhesion. **Alcoholism Clin. Exp. Res.** 20(9 Suppl.):350A-355A, 1996.doi:10.1111/j.1530-0277.1996.tb01806.x.
278. Fukumura, D., Miura, S., Kurose, I., Higuchi, H., **Suzuki, H.**, Ebinuma, H., Han, J-Y., Watanabe, N., Wakabayashi, G., Kitajima, M., Ishii, H. IL-1 is an important mediator for microcirculatory changes in endotoxin-induced intestinal mucosal damage. **Dig. Dis. Sci.** 41(12):2482-2492, 1996.doi:10.1007/BF02100147.
279. **Suzuki, H.**, Zweifach, B.W., Schmid-Schönbein, G.W. Dependence of elevated mesenteric arteriolar tone on glucocorticoids in spontaneously hypertensive rats. **Int. J. Microcirc. Clin. Exp.** (incorporated into **J. Vasc. Res.**) 15(6):309-315, 1995.doi:10.1159/000179080.
280. **Suzuki, H.**, Miura, S., Liu, Y.Y., Tsuchiya, M., Ishii, H. Substance P induces degranulation of mast cells and leukocyte adhesion to venular endothelium. **Peptides** 16(8):1447-1452, 1995.doi:10.1016/0196-9781(95)02050-0.
281. **Suzuki, H.**, Poole, D.C., Zweifach, B.W., Schmid-Schönbein, G.W. Temporal correlation between maximum tetanic force and cell death in postischemic rat skeletal muscle. **J. Clin. Invest.** 96(6):2892-2897, 1995.doi:10.1172/JCI118630.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



282. **Suzuki, H.**, Zweifach, B.W., Schmid-Schönbein, G.W. Vasodilator response of mesenteric arterioles to histamine in spontaneously hypertensive rats. **Hypertension** 26(3):397-400, 1995.doi:10.1161/01.HYP.26.3.397.
283. **Suzuki, H.**, Sweil, A., Zweifach, B.W., Schmid-Schönbein, G.W. *In vivo* evidence for microvascular oxidative stress in spontaneously hypertensive rats - Hydroethidine microfluorography - **Hypertension** 25(5):1083-1089, 1995. doi:10.1161/01.HYP.25.5.1083.
284. **Suzuki, H.**, Zweifach, B.W., Forrest, M.J., Schmid-Schönbein, G.W. Modification of leukocyte adhesion in spontaneously hypertensive rats due to adrenal corticosteroids. **J. Leukoc. Biol.** 57(1):20-26, 1995.
285. Kurose, I., Miura, S., Fukumura, D., **Suzuki, H.**, Tsuchiya, M., Ishii, H. Inhibition of platelet-activating factor production and granulocyte oxidative activation by Rikkunshi-To in the process of gastric mucosal injury. **Pathophysiology** 2:153-159, 1995.doi:10.1016/0928-4680 (95)00030-5.
286. Suematsu, M., **Suzuki, H.**, Tamatani, T., Iigou, Y., Delano, F.A., Miyasaka, M., Forrest, M.J., Kannagi, R., Zweifach, B.W., Ishimura, Y., Schmid-Schönbein, G.W. Impairment of selectin-mediated leukocyte adhesion to venular endothelium in spontaneously hypertensive rats. **J. Clin. Invest.** 96(4):2009-2016, 1995.doi:10.1172/JC/118248.
287. Tanaka, S., Miura, S., **Suzuki, H.**, Ohkubo, N., Imaeda, H., Shiozaki, H., Tashiro, H., Serizawa, H., Tsuchiya, M. Immunohistochemical study of rat Peyer's patches in peptidoglycan-polysaccharide complex-induced chronic enteritis. **Adv. Exp. Med. Biol.** 371B:1395-1398, 1995.
288. **Suzuki, H.**, Hibi, T., Oda, M., Hosoda, Y., Mori, M., Miura, S., Tanaka, S., Watanabe, M., Tsuchiya, M. Sulfhydryl blockers-induced colitis in the rat - immunological changes in thymus gland and colonic mucosa -. **J. Gastroenterol. Hepatol.** 9(6):544-550, 1994.doi:10.1111/j.1440-1746.1994.tb01558.x.
289. **Suzuki, H.**, Schmid-Schönbein, G.W., Suematsu, M., DeLano, F.A., Forrest, M.J., Miyasaka, M., Zweifach, B.W. Impaired leukocyte-endothelial interaction in spontaneously hypertensive rats. **Hypertension** 24(6):719-727, 1994. doi:10.1161/01.HYP.24.6.719.
290. **Suzuki, H.**, Suematsu, M., Miura, S., Liu, Y.Y., Watanabe, K., Tsurufuji, S., Miyasaka, M., Tsuchiya, M. Rat CINC/gro: a novel mediator for locomotive and secretagogue activation of neutrophils *in vivo*. **J. Leukoc. Biol.** 55(5):652-657, 1994.
291. **Suzuki, H.**, Suematsu, M., Ishii, H., Kato, S., Miki, H., Mori, M., Ishimura, Y., Nishino, T., Tsuchiya, M. Prostaglandin E<sub>1</sub> abrogates early reductive stress and zone-specific paradoxical oxidative injury in hypoperfused rat liver. **J. Clin. Invest.** 93(1):155-164, 1994.doi:10.1172/JCI116939.
292. Suzuki, M., Miura, S., Mori, M., Kai, A., **Suzuki, H.**, Fukumura, D., Suematsu, M., Tsuchiya, M. Rebamipide, a novel antiulcer agent, attenuates *Helicobacter pylori* induced gastric mucosal cell injury associated with neutrophil derived oxidants. **Gut** 35(10):1375-1378, 1994.doi:10.1136/gut.35.10.1375.
293. Tashiro, H., Miura, S., Kurose, I., Fukumura, D., **Suzuki, H.**, Suematsu, M., Yoshioka, M., Tsuchiya, M., Kai, A., Kudoh, Y. Verotoxin induces hemorrhagic lesions in rat small intestine. Temporal alterations of vasoactive substances. **Dig. Dis. Sci.** 39(6):1230-1238, 1994.doi:10.1007/BF02093788.
294. Suematsu, M., Tamatani, T., DeLano, F.A., Miyasaka, M., Forrest, M.J., **Suzuki, H.**, Schmid-Schönbein, G.W. Microvascular oxidative stress preceding leukocyte activation elicited by *in vivo* nitric oxide suppression. **Am. J. Physiol., Heart & Circ. Physiol.** 266(6 Pt 2):H2410-2415, 1994.
295. **Suzuki, H.**, Suematsu, M., Miura, S., Asako, H., Kurose, I., Ishii, H., Houzawa, S., Tsuchiya, M. Xanthine oxidase-mediated intracellular oxidative stress in response to cerulein in rat pancreatic acinar cells. **Pancreas** 8(4):465-470, 1993.
296. Oda, M., Kaneko, H., Suematsu, M., **Suzuki, H.**, Kazemoto, S., Honda, K., Yonei, Y., Tsuchiya, M. A new aspect of the hepatic microvasculature: electron-microscopic evidence for the presence of Ito cells around portal and hepatic venules as pericytes. **Prog. Appl. Microcirc.** 19:25-39, 1993.
297. Suzuki, M., Miura, S., Suematsu, M., Fukumura, D., **Suzuki, H.**, Kai, A., Tsuchiya, M. *Helicobacter pylori* elicits gastric mucosal cell damage associated with neutrophil-derived toxic oxidants. **Eur. J. Gastroenterol. Hepatol.** 5:S35-S39, 1993.
298. Suematsu, M., Oda, M., **Suzuki, H.**, Kaneko, H., Watanabe, N., Furusho, T., Masushige, S., Tsuchiya, M. Intravital and electron microscopic observation of Ito cells in the rat hepatic microcirculation. **Microvasc. Res.** 46(1):28-42, 1993.doi:10.1006/mvres.1993.1033.
299. Suzuki, M., Miura, S., Suematsu, M., Fukumura, D., Kurose, I., **Suzuki, H.**, Kai, A., Kudoh, Y., Ohashi, M., Tsuchiya, M. *Helicobacter pylori*-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury. **Am. J. Physiol., Gastrointest. Liver Physiol.** 263(5 Pt 1):G719-725, 1992.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



300. Suematsu, M., **Suzuki, H.**, Ishii, H., Kato, S., Hamamatsu, H., Miura, S., Tsuchiya, M. Topographic dissociation between mitochondrial dysfunction and cell death during low-flow hypoxia in perfused rat liver visualized by dual-color digital microfluorography. **Lab. Invest.** 67(4):434-442, 1992.
301. Suematsu, M., **Suzuki, H.**, Ishii, H., Kato, S., Yanagisawa, T., Asako, H., Suzuki, M., Tsuchiya, M. Early midzonal oxidative stress preceding cell death in hypoperfused rat liver. **Gastroenterology** 103(3):994-1001, 1992.
302. Liu, YY., Miura, S., **Suzuki, H.**, Kurose, I., Fukumura, D., Suzuki, M., Suematsu, M., Tsuchiya, M. Quantitative analysis of mesenteric microcirculatory disturbances induced by autonomic nervous irritation. **Keio J. Med.** 41(3):128-133, 1992.
303. Watanabe, K., Suematsu, M., Iida, M., Takaishi, K., Iizuka, Y., **Suzuki, H.**, Suzuki, M., Tsuchiya, M., Tsurufuji, S. Effect of rat CINC/gro, a member of the interleukin-8 family, on leukocytes in microcirculation of the rat mesentery. **Exp. Mol. Pathol.** 56(1):60-69, 1992.doi:10.1016/0014-4800(92)90023-5.
304. Kato, S., Suematsu, M., **Suzuki, H.**, Ishii, H., Tsuchiya, M. Analysis of free radical production by fluorescent probes in CCl<sub>4</sub>-induced liver injury. **J. Toxicol. Sci.** 16 (Suppl. 2):79-82, 1991.doi:10.2131/jts.16.Supplement11-79.
305. Suematsu, M., Kato, S., Ishii, H., Yanagisawa, T., Asako, H., **Suzuki, H.**, Oshio, C., Tsuchiya, M. Intralobular heterogeneity of carbon tetrachloride-induced oxidative stress visualized by digital imaging fluorescence microscopy. **Lab. Invest.** 64(2):167-173, 1991.

### 1.2 Review articles in English (105)

1. **Suzuki H.\*** Editorial: An important milestone for systematizing gastroparesis practice. **United European Gastroenterol J.** 2021 Apr;9(3):285-286. doi: 10.1002/ueg2.12064.
2. **Suzuki H.\*** Recent Advances in the Definition and Management of Functional Dyspepsia. **Keio J Med.** 2021 Mar 25;70(1):7-18. doi: 10.2302/kjm.2020-0006-OA.
3. Mori, H., Tack J., **Suzuki H.\*** Magnesium Oxide in Constipation. **Nutrients** 13(2):421; 2021. <https://doi.org/10.3390/nu13020421>
4. Gwee, K.A., Holtmann, G., Tack, J., **Suzuki H.**, Liu, J., Xiao, Y., Chen, M.H., Hou, X., Wu, D.C., Toh, C., Lu, F., Tang, X.D. Herbal medicines in functional dyspepsia-Untapped opportunities not without risks. **Neurogastroenterol Motil.** 2021 Feb;33(2):e14044. doi: 10.1111/nmo.14044.
5. **Suzuki H.\***, Mori, H. Single-capsule bismuth quadruple therapy: Preferable at the moment, but what should be next? **United European Gastroenterol J.** 2021 Feb;9(1):7-8. doi: 10.1177/2050640620975357.
6. Klionsky, D.J., Abdelmohsen, K., **Suzuki, H.**, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4<sup>th</sup> edition) **Autophagy** 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280.
7. Nishizawa, T.; **Suzuki H.\*** Long-Term Outcomes of Endoscopic Submucosal Dissection for Superficial Esophageal Squamous Cell Carcinoma. **Cancers** (Basel) 2020 Oct 2;12(10):2849. doi: 10.3390/cancers12102849.
8. Mori, H., Tack J., **Suzuki H.\*** Statements for conducting high-resolution manometry during the COVID-19 pandemic. **J Clin Biochem Nutr.** 2020;67(2):114-115. doi: 10.3164/jcfn.20-97.
9. Scarpellini E, Arts J, Karamanolis G, Laurenus A, Siquini W, **Suzuki H**, Ukleja A, Van Beek A, Vanuytsel T, Bor S, Ceppa E, Di Lorenzo C, Emous M, Hammer H, Hellström P, Laville M, Lundell L, Masclee A, Ritz P, Tack J. International consensus on the diagnosis and management of dumping syndrome. **Nat Rev Endocrinol.** 2020 Aug;16(8):448-466. doi: 10.1038/s41574-020-0357-5.
10. Mori H, **Suzuki H.\*** Update on quinolone-containing rescue therapies for *Helicobacter pylori* infection. **World J Gastroenterol.** 2020 Apr 21;26(15):1733-1744. doi: 10.3748/wjg.v26.i15.1733.
11. Jung HK, Hong SJ, Lee OY, Pandolfino J, Park H, Miwa H, Ghoshal UC, Mahadeva S, Oshima T, Chen M, Chua ASB, Cho YK, Lee TH, Min YW, Park CH, Kwon JG, Park MI, Jung K, Park JK, Jung KW, Lim HC, Jung DH, Kim DH, Lim CH, Moon HS, Park JH, Choi SC, **Suzuki H**, Patcharatrakul T, Wu JCY, Lee KJ, Tanaka S, Siah KTH, Park KS, Kim SE; Korean Society of Neurogastroenterology and Motility. 2019 Seoul Consensus on Esophageal Achalasia Guidelines. **J Neurogastroenterol Motil.** 2020 Apr 30;26(2):180-203. doi: 10.5056/jnm20014.
12. Matsuzaki J, Tsugawa H, **Suzuki H.\*** Precision Medicine Approaches to Prevent Gastric Cancer. **Gut Liver** 15(1):3-12, 2021. doi: 10.5009/gnl19257.
13. Nishizawa T, **Suzuki H**, Higuchi H, Ebinuma H, Toyoshima O. Effects of encircled abdominal compression device in colonoscopy: A meta-analysis. **J Clin Med.** 2019;9(1):11. doi: 10.3390/jcm9010011.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



14. **Suzuki H.\*** Balancing act: The need for work style reform for young and/or female gastroenterologists. **Dig Dis Sci.** 2019;65(1):1-2. doi: 10.1007/s10620-019-05871-5.
15. Gwee KA, Gonlachanvit S, Ghoshal UC, Chua ASB, Miwa H, Wu J, Bak YT, Lee OY, Lu CL, Park H, Chen M, Syam AF, Abraham P, Sollano J, Chang CS, **Suzuki H**, Fang X, Fukudo S, Choi MG, Hou X, Hongo M. Second Asian Consensus on Irritable Bowel Syndrome. **J Neurogastroenterol Motil.** 2019 Jul 1;25(3):343-362. doi: 10.5056/jnm19041.
16. Pauwels A, Boeckstaens V, Andrews CN, Attwood SE, Berrisford R, Bisschops R, Boeckstaens GE, Bor S, Bredenoord AJ, Cicala M, Corsetti M, Fornari F, Gyawali CP, Hatlebakk J, Johnson SB, Lerut T, Lundell L, Mattioli S, Miwa H, Nafteux P, Omari T, Pandolfino J, Penagini R, Rice TW, Roelandt P, Rommel N, Savarino V, Sifrim D, **Suzuki H**, Tutuian R, Vanuytsel T, Vela MF, Watson DI, Zerbib F, Tack J. How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery). **Gut** 2019 Nov;68(11):1928-1941. doi: 10.1136/gutjnl-2019-318260.
17. **Suzuki, H.\*** Editorial: To establish a treatment for GI symptoms of cystic fibrosis, it is necessary to develop a symptom evaluation tool. **United European Gastroenterology Journal** 7(7):873-874, 2019. doi: 10.1177/2050640619856188. PubMed PMID: 31428410; PubMed Central PMCID: PMC6683642.
18. Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, **Suzuki H**, Handa O, Furuta T, Mabe K, Murakami K, Sugiyama T, Uemura N, Takahashi S. Guidelines for the management of *Helicobacter pylori* infection in Japan: 2016 Revised Edition. **Helicobacter** 2019 Aug;24(4):e12597. doi: 10.1111/hel.12597. Epub 2019 May 20.
19. Mori H, **Suzuki, H.\*** Role of acid suppression in acid-related diseases: PPI and P-CAB. **J Neurogastroenterol Motil.** 25(1):6-14, 2019. doi: 10.5056/jnm18139. doi: 10.5056/jnm18139.
20. **Suzuki, H.\*** Introduction to serial reviews: Oxidative stress and digestive diseases. **J. Clin. Biochem. Nutri.** 63(1):5, 2018.
21. **Suzuki, H.\*** New pharmacological treatments for gastroesophageal reflux: p-cab and bile acid sequestrants. **NeuroGastroLATAM Reviews** 2(1):18-27, 2018. doi:10.24875/NGL.18000007
22. Kobayakawa M, Ohnishi S, **Suzuki H**. Recent development of balloon-occluded retrograde transvenous obliteration. **J Gastroenterol Hepatol.** 2018 Aug 31. doi:10.1111/jgh.14463.
23. **Suzuki, H.\***, Matsuzaki, J. Gastric cancer: evidence boosts *H. pylori* eradication. **Nature Rev. Gastroenterol. Hepatol.** 15(8):458-460, 2018. doi:10.1038/s41575-018-0023-8. Epub 30 April 2018.
24. Nishizawa, T., **Suzuki, H.\*** Propofol for Gastrointestinal Endoscopy. **United European Gastroenterol Journal.** 6(6):801-805, 2018. <https://doi.org/10.1177/2050640618767594>.
25. Mori, H., **Suzuki, H.\*** Reply to the letter to the editor: *H. pylori* test-and-treat should not be put off for gastric cancer prevention in East Asia any longer. **J. Gastroenterol.** 53(6):789-790, 2018. doi: 10.1007/s00535-018-1454-2.
26. **Suzuki, H.\*** New medical approach to functional dyspepsia, from core symposium 3, Japan Gastroenterological Association 2015-2017. **Digestion** 97(1):6-12, 2018 doi: 10.1159/000484029.
27. **Suzuki, H.\***, Matsuzaki, J. *Helicobacter pylori* eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk. **Gut** 2017 Dec. 15, doi: 10.1136/gutjnl-2017-315698.
28. **Suzuki, H.\***, Mori, H. World trends for *H. pylori* eradication therapy and gastric cancer prevention strategy by *H. pylori* test-and-treat. **J. Gastroenterol.** 53(3):354-361, 2018 doi: 10.1007/s00535-017-1407-1.
29. Nishizawa, T., **Suzuki, H.\***, Hosoe, N., Ogata, H., Kanai, T., Yahagi, N. Dexmedetomidine vs propofol for gastrointestinal endoscopy: A meta-analysis. **United European Gastroenterol Journal** 5(7):1037-1045, 2017. doi: 10.1177/2050640616688140. (IF: 3.673).
30. **Suzuki, H.\*** The Application of the Rome IV Criteria to Functional Esophagoduodenal Disorders in Asia. **J. Neurogastroenterol. Motil.** 23(3):325-333, 2017. doi:10.5056/jnm17018.
31. Nishizawa, T., **Suzuki, H.\***, Goto, O., Ogata, H., Kanai, T., Yahagi, N. Effect of prophylactic clipping in colorectal endoscopic resection: A meta-analysis of randomized controlled studies. **United European Gastroenterol Journal** 5(6):859-867, 2017. doi: 10.1177/2050640616687837.
32. **Suzuki, H.\*** *Helicobacter pylori*-Associated Upper Gastrointestinal Symptoms:FD or HpD? **Dig. Dis. Sci.** ;62(6):1391-1393, 2017. doi:10.1007/s10620-14-4556-4.
33. Nishizawa, T., Masaoka, T., **Suzuki, H.\***. Functional Dyspepsia: Pathogenesis, Diagnosis, and Treatment. **J. Gen. Family Med.** 17(3):204-210, 2016. doi: 10.14442/jgfm.17.3\_204.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



34. **Suzuki, H.\***, Mori, H. Different pathophysiology of gastritis between East and West? An Asian perspective. **Inflamm. Intest. Dis** 1(3):123-128, 2016. doi: 10.1159/000446301.
35. Stanghellini, V., Chan, F. K-L, Hasler, W.L., Malangelada, J.R., **Suzuki, H.**, Tack, J., Talley, N.J. Gastrointestinal Disorders. **Gastroenterology** 150:1380-1392, 2016. doi:10.1053/j.gastro.2016.02.011.
36. Mori, H., **Suzuki, H.\*** Reply to letter to the editor: "The dosage of rifabutin in *H. pylori* eradication regimen should be appropriately determined in each area of the world" **United European Gastroenterology Journal** 4(3):476-477, 2016.
37. Ueda, M., Iwasaki, E., **Suzuki H.\*** Profile of acotiamide in the treatment of functional dyspepsia. **Clin. Exp. Gastroenterol.** 9:83-88, 2016.doi:10.1080/15548627.2015.1100356.
38. Klionsky, D.J., Abdelmohsen, K., Abe, A., Abedin, M.J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C.M., **Suzuki, H.** et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3<sup>rd</sup> edition). **Autophagy** 12(1):1-222, 2016.
39. Horibe, M., Nishizawa, T., **Suzuki, H.**, Minami, K., Yahagi, N., Iwasaki, E., Kanai, K. Timing of oral refeeding in acute pancreatitis: A systematic review and meta-analysis. **United European Gastroenterology Journal** 4(6):725-732, 2016. doi: 10.1177/2050640615612368.
40. Matsushita M, Masaoka T, **Suzuki H.\*** Emerging treatments in neurogastroenterology: Acotiamide, a novel treatment option for functional dyspepsia. **Neurogastroenterol Motil.** Jan 5, 2016. doi: 10.1111/nmo.12756.
41. Nishizawa, T., **Suzuki, H.\***, Fujimoto, A., Ochiai, Y., Kanai, T., Yahagi, N. Effects of carbon dioxide insufflation in balloon-assisted enteroscopy: A systematic review and meta-analysis **United European Gastroenterology Journal** 4(1):11-7, 2016. doi:10.1177/2050640615588024.
42. Nishizawa, T., **Suzuki, H.\***, Akimoto, T., Maehata, T., Kanai, T., Morizane, T., Yahagi, N. Effects of preoperative proton pump inhibitor administration on bleeding after gastric endoscopic submucosal dissection: A systematic review and meta-analysis **United European Gastroenterology Journal** 4(1):5-10, 2016.doi:10.1177/2050640615588023.
43. **Suzuki, H.\***, Mori, H. *Helicobacter pylori*: *Helicobacter pylori* gastritis-a novel distinct disease entity. **Nature Rev. Gastroenterol. Hepatol.** 12(10):556-557, 2015. doi:10.1038/nrgastro.2015.158.
44. Matsuzaki, J., **Suzuki, H.\*** Role of *microRNAs-221/222* in digestive systems. **J. Clin. Med.** 4(8):1566-1577, 2015. doi:10.3390/jcm4081566.
45. Tomoda, A., Kamiya, S., **Suzuki, H.** Editorial: *Helicobacter pylori* and pathogenesis. **BioMed. Res. Int.** 2015:304768, 2 pages, 2015. doi: 10.1155/2015/304768.
46. Chen, S.L., Gwee, K.A., Lee, J.S., Miwa, H., **Suzuki, H.**, Guo, P., Hao, Y.T., Chen, M.H. Letter: Prompt endoscopy in Asians with uninvestigated dyspepsia - authors' reply. **Aliment. Pharm. Ther.** 41(8):793, 2015.
47. Nishizawa, T., **Suzuki, H.\***, Kanai, T., Yahagi, N. Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissection-induced ulcer: a systematic review. **J. Clin. Biochem. Nutri.** 56(2):85-90, 2015.doi:10.3164/jcfn.14-101.
48. Miwa, H., Kusano, M., Arisawa, T., Oshima, T., Kato, M., Joh, T., **Suzuki, H.**, Tominaga, K., Nakada, K., Nagahara, A., Futagami, S., Manabe, N., Inui, A., Haruma, K., Higuchi, K., Yakabi, K., Hongo, M., Uemura, N., Kinoshita, Y., Sugano, K., Shimosegawa, T. Evidence-based clinical practice guidelines for functional dyspepsia. **J. Gastroenterol.** 50(2):125-139, 2015.doi:10.1007/s00535-014-1022-3.
49. Nishizawa T, **Suzuki H.** Reply to letter: "Dexmedetomidine vs midazolam for gastrointestinal endoscopy". **Digest. Endosc.** 27(4):533, 2015.doi:10.1111/den.12459.
50. Chen, S.L., Gwee, K.A., Lee, J.S., Miwa, H., **Suzuki, H.**, Guo, P., Hao, Y.T., Chen, M.H. Systematic review with meta-analysis: prompt endoscopy as the initial management strategy for uninvestigated dyspepsia in Asia. **Aliment. Pharm. Ther.** 41:239-252, 2015.doi:10.1111/apt.13028.
51. Nishizawa, T., Nishizawa, Y., Yahagi, N., Kanai, T., Takahashi, M., **Suzuki, H.\*** Effect of supplementation with rebamipide for *Helicobacter pylori* eradication therapy: a systematic review and meta-analysis. **J. Gastroenterol. Hepatol.** 29(S4):20-24, 2014.doi:10.1111/jgh.12769.
52. Nishizawa, T., **Suzuki, H.\*** Gastric carcinogenesis and underlying molecular mechanisms: *Helicobacter pylori* and novel targeted therapy. **Biomed. Res. Int.** 2015:794378, 7 pages, 2015.doi:10.1155/2015/794378.



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



53. Nishizawa, T., **Suzuki, H.\***, Kinoshita, S., Goto, O., Kanai, T., Yahagi, N. Second-look endoscopy after endoscopic submucosal dissection for gastric neoplasms: A systematic review. **Digest. Endosc.** 27(3):279-284, 2015.doi:10.1111/den.12410.
54. Nishizawa, T., **Suzuki, H.\*** Mechanisms of *Helicobacter pylori* antibiotic resistance and molecular testing. **Front. Mol. Biosci.** 1:19. 2014.doi: 10.3389/fmolb.2014.00019.
55. Nishizawa T, **Suzuki, H.\***, Sagara S, Kanai T, Yahagi N. Dexmedetomidine versus midazolam for gastrointestinal endoscopy: A meta-analysis. **Digest. Endosc.** 27(1):8-15, 2015.doi:10.1111/den.12399.
56. Nishizawa, T., **Suzuki, H.\***, Matsuzaki, J., Kanai, T., Yahagi, N. Propofol vs traditional sedative agents for endoscopic submucosal dissection: A systematic review. **Digest. Endosc.** 26(6):701-706, 2014.doi:10.1111/den.12342.
57. Masaoka, T., **Suzuki, H.\*** Does the AIMS65, a new risk score for upper gastrointestinal bleeding, work in Japan? **Digest. Endosc.** 26(3):331-332, 2014.doi:10.1111/den.12224.
58. Masaoka, T., **Suzuki, H.\*** Does bile reflux influence the progression of Barrett's esophagus to adenocarcinoma? **J. Neurogastroenterol. Motil.** 20(1):124-126, 2014.doi:10.5056/jnm.2014.20.1.124.
59. Matsuzaki, J., **Suzuki, H.\*** MicroRNAs in Barrett's esophagus: Future prospects. **Front. Genet.** 5:69, 2014.doi:10.3389/fgene.2014.00069.
60. Nishizawa, T., **Suzuki, H.\*** Endoscopic microvascular patterns of gastrointestinal cancer. **Microvasc. Rev. Commun.** 6(1): 9-12, 2013.doi:10.14532/mvrc.6.9.
61. Masaoka, T., **Suzuki, H.\*** Do we need to eradicate *H. pylori* in patients with GORD? **United European Gastroenterology Journal** 1(4):223-225, 2013.doi:10.1177/2050640613497713.
62. Nishizawa, T., **Suzuki, H.\*** The role of *microRNA* in gastric malignancy. **Int. J. Mol. Sci.** 14(5):9487-9496, 2013.doi:10.3390/ijms14059487.
63. **Suzuki, H.\***, Moayyedi, P. *Helicobacter pylori* infection in functional dyspepsia. **Nature Rev. Gastroenterol. Hepatol.** 10(3):168-74, 2013.doi:10.1038/nrgastro.2013.9.
64. **Suzuki, H.\***, Nishizawa, T., Tsugawa, H., Hibi, T. Molecular approaches and modern clinical strategies for the management of *Helicobacter pylori* infection in Japan. **Keio J. Med.** 61(4):109-119, 2012.doi:10.2302/kjm.2012-0001-RE.
65. **Suzuki, H.\***, Matsuzaki, J. Are solifenacin and ramosetron really ideal to treat irritable bowel syndrome?: Author's Reply. **J. Neurogastroenterol. Motil.** 18(4):459, 2012. doi:10.5056/jnm.2012.18.4.459.
66. **Suzuki, H.\***, Nishizawa, T., Tsugawa, H., Mogami, S., Hibi, T. Roles of oxidative stress in stomach disorders. **J. Clin. Biochem. Nutri.** 50(1):35-39, 2012.doi:10.3164/jcfn.11-115SR.
67. Saito, Y., **Suzuki, H.\***, Matsuura, M., Sato, A., Kasai, Y., Yamada, K., Saito, H., Hibi, T. MicroRNAs in hepatobiliary and pancreatic cancers. **Front. Genet.** 2:66, 2011. doi:10.3389/fgene.2011.00066.
68. **Suzuki, H.\***, Hibi, T. Overlap syndrome of functional dyspepsia and irritable bowel syndrome - are both diseases mutually exclusive? -. **J. Neurogastroenterol. Motil.** 17(4):360-365, 2011.doi:10.5056/jnm.2011.17.4.360.
69. **Suzuki, H.\***, Matsuzaki, J., Hibi, T. Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy for *Helicobacter pylori* eradication? **Expert Rev. Clin. Pharmacol.** 4(5):579-582, 2011.doi:10.1586/ecp.11.34.
70. **Suzuki, H.\***, Franceschi, F., Nishizawa, T., Gasbarrini, A. Extragastric manifestations of *Helicobacter pylori* infection. **Helicobacter** 16(Suppl.1):65-69, 2011.doi:10.1111/j.1523-5378.2011.00883.x.
71. **Suzuki, H.\***, Okada, S., Hibi, T. Proton pump inhibitors for the treatment of functional dyspepsia. **Ther. Adv. Gastroenterol.** 4(4):219-226, 2011. doi:10.1177/1756283x11398735.
72. **Suzuki, H.\***, Matsuzaki, J, Hibi, T. What is the difference between *Helicobacter pylori*-associated dyspepsia and functional dyspepsia? **J. Neurogastroenterol. Motil.** 17(2): 124-130, 2011.doi:10.5056/jnm.2011.17.2.124.
73. **Suzuki, H.\***, Nishizawa, T., Hibi, T. Can *Helicobacter pylori*-associated dyspepsia be categorized as functional dyspepsia? **J. Gastroenterol. Hepatol.** 26(s3):42-45, 2011.doi:10.1111/j.1440-1746.2011.06629.x.
74. **Suzuki, H.\***, Matsuzaki, J., Hibi, T. Ghrelin and oxidative stress in gastrointestinal tract. **J. Clin. Biochem. Nutri.** 48(2):122-125, 2011.doi:10.3164/jcfn.10-16GFR.
75. **Suzuki, H.\***, Nishizawa, T., Hibi, T. *Helicobacter pylori* eradication therapy. **Future Microbiol.** 5(4):639-648, 2010.doi:10.2217/fmb.10.25.





# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



76. **Suzuki, H.\***, Hibi, T. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia. **Neurogastroenterol. Motil.** 22(6):595-599, 2010. doi:10.1111/j.1365-2982.2010.01486.x.
77. **Suzuki, H.\*** Post-infectious functional dyspepsia- a novel disease entity among functional GI disorders - Relation to *H. pylori* infection? **J. Neurogastroenterol. Motil.** 16(1):97-98, 2010. doi:10.5056/jnm.2010.13.1.97.
78. **Suzuki, H.\***, Suzuki, M., Imaeda, H., Hibi, T. *Helicobacter pylori* and microcirculation. **Microcirculation** 16(7):547-558, 2009.
79. **Suzuki, H.\***, Iwasaki, E., Hibi, T. *Helicobacter pylori* and gastric cancer. **Gastric Cancer** 12(2):79-87, 2009. doi:10.1007/s10120-009-0507-x.
80. **Suzuki, H.\***, Saito, Y., Hibi, T. *Helicobacter pylori* and gastric MALT lymphoma: updated review of clinical outcomes and the molecular pathogenesis. **Gut and Liver** 3(2):81-87, 2009.
81. **Suzuki, H.\***, Inadomi, J.M., Hibi, T. Japanese herbal medicine in functional gastrointestinal disorders. **Neurogastroenterol. Motil.** 21(7):688-696, 2009. doi:10.1111/j.1365-2982.2009.01290.x.
82. Nishizawa, T., **Suzuki, H.\***, Hibi, T. Quinolone-based third-line therapy for *Helicobacter pylori* eradication. **J. Clin. Biochem. Nutri.** 44(2):119-124, 2009. doi:10.3164/jcfn.08-220R.
83. Saito, Y., **Suzuki, H.\***, Hibi, T. The role of *microRNAs* in gastrointestinal cancers. **J. Gastroenterol.** 44(Suppl.19):18-22, 2009. doi:10.1007/s00535-008-2285-3.
84. Asano, K., **Suzuki, H.** Silent acid reflux and asthma control. **N. Engl. J. Med.** 360(15):1551-1553, 2009.
85. Masaoka, T., **Suzuki, H.\***, Hibi, T. Gastric epithelial cell modality and proton pump inhibitor. **J. Clin. Biochem. Nutri.** 42(3):191-196, 2008.
86. Suzuki, M., **Suzuki, H.**, Hibi, T. Proton pump inhibitors and gastritis. **J. Clin. Biochem. Nutri.** 42(2):71-75, 2008.
87. **Suzuki, H.\***, Hibi, T., Marshall, B.J. *Helicobacter pylori* : present status and future prospects in Japan. **J. Gastroenterol.** 42(1):1-15, 2007. doi:10.1007/s00535-006-1990-z.
88. **Suzuki, H.\***, Marshall, B.J., Hibi, T. Overview: *Helicobacter pylori* and extra-gastric disease. **Int. J. Hematol.** 84(4):291-300, 2006. doi:10.1532/IJH97.06180.
89. **Suzuki, H.\***, Masaoka, T., Hibi, T. Ghrelin – a novel appetite-stimulating hormone, which also affects gastrointestinal functions -. **Korean J. Gastroenterol.** 48(2):82-88, 2006.
90. **Suzuki, H.\***, Hibi, T. Oxidative stress in *Helicobacter pylori* -associated gastroduodenal disease. **J. Clin. Biochem. Nutri.** 39(2):56-63, 2006. doi:10.3164/jcfn.39.56.
91. **Suzuki, H.\***, Nishizawa, T., Hibi, T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. **J. Gastroenterol.** 41(6):513-523, 2006. doi:10.1007/s00535-006-1847-5.
92. **Suzuki H.**, Masaoka T, Hibi T. [Ghrelin - a novel appetite-stimulating hormone which also affects gastrointestinal functions]. **Korean J Gastroenterol.** 2006; 48(2): 82-88.
93. Naito, Y., Ito, M., Watanabe, T., **Suzuki, H.** (All authors contributed equally) Biomarkers in patients with gastric inflammation: a systematic review. **Digestion** 72(2-3):164-180, 2005. doi:10.1159/000088396.
94. **Suzuki, H.\***, Nishizawa, T., Masaoka, T., Mori, M., Iwasaki, E., Tsuchimoto, K., Hibi, T. *Helicobacter pylori* infection and gastric cancer. **JMAJ** 48(10):497-504, 2005.
95. **Suzuki, H.\***, Hibi, T. Does *Helicobacter pylori* attack ghrelin-producing cells? **J. Gastroenterol.** 40(4):437-9, 2005. doi:10.1007/s00535-005-1568-1.
96. **Suzuki, H.\***, Hibi, T. Novel effects other than antisecretory action and off-label use of proton pump inhibitors. **Expert. Opin. Pharmacother.** 6(1):59-67, 2005. doi:10.1517/14656566.6.1.59.
97. **Suzuki, H.**, Masaoka, T., Nomura, S., Hoshino, Y., Kurabayashi, K., Minegishi, Y., Suzuki, M., Ishii, H. Current consensus on the diagnosis and treatment of *H. pylori* -associated gastroduodenal disease. **Keio J. Med.** 52 (3):163-173, 2003. doi:10.2302./kjm.52.163.
98. **Suzuki, H.**, Masaoka, T., Miyazawa, M., Suzuki, M., Miura, S., Ishii, H. Gastric mucosal response to *Helicobacter pylori*. **Keio J. Med.** 51(Suppl.2):40-44, 2002. doi:10.2302/kjm.51.supplement2\_10.



# SIDDS 2022

Seoul International Digestive Disease Symposium 2022

In conjunction with the annual meeting of Korean Society of Gastroenterology

April 16-17, 2022 Virtual Congress



99. Suematsu, M., **Suzuki, H.**, DeLano, F.A., Schmid-Schönbein, G.W. Inflammatory aspects of the microcirculation in hypertension: oxidative stress, leukocytes/endothelial interaction, apoptosis. **Microcirculation** 9(4):259-276, 2002.
100. **Suzuki, H.**, Yamabe, K., Ishii, H. *Helicobacter pylori* -current topics-. **Asian Med. J.** 43:343-348, 2000.
101. **Suzuki, H.**, Ishii, H. Role of apoptosis in *Helicobacter pylori* -associated gastric mucosal injury. **J. Gastroenterol. Hepatol.** 15(Suppl.):D46-D54, 2000.doi:10.1046/j.1440-1746.2000.02147.x.
102. **Suzuki, H.**, Suematsu, M., Schmid-Schönbein, G.W. Microvascular oxidative stress, immune reaction and apoptosis in hypertensives. **Clin. Hemorheol. Microcirc.** 21(3-4):161-168,1999.
103. **Suzuki, H.**, Miura, S., Suzuki, M., Terada, S., Nakamura, M., Tsuchiya, M. Gastric mucosal injury - microcirculation and *Helicobacter pylori* - **Keio J. Med.** 43(1):1-8, 1994. doi:10.2302/kjm.43.1.
104. Tsuchiya, M., Suematsu, M., **Suzuki, H.** *In vivo* visualization of oxygen radical-dependent photoemission. **Meth. Enzymol.** 233:128-140, 1994.doi:10.1016/s0076-6879(94)33015-8.